CN1142829A - 用于真核细胞中定点突变的化合物和方法 - Google Patents
用于真核细胞中定点突变的化合物和方法 Download PDFInfo
- Publication number
- CN1142829A CN1142829A CN94194935A CN94194935A CN1142829A CN 1142829 A CN1142829 A CN 1142829A CN 94194935 A CN94194935 A CN 94194935A CN 94194935 A CN94194935 A CN 94194935A CN 1142829 A CN1142829 A CN 1142829A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- district
- cell
- chimeric
- hybrid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 28
- 210000003527 eukaryotic cell Anatomy 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 title description 4
- 230000035772 mutation Effects 0.000 title description 4
- 239000013598 vector Substances 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 150000007523 nucleic acids Chemical class 0.000 claims description 43
- 230000008859 change Effects 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 19
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 9
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 9
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 238000010396 two-hybrid screening Methods 0.000 claims description 6
- 230000008521 reorganization Effects 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 210000004681 ovum Anatomy 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 27
- 108091028664 Ribonucleotide Proteins 0.000 abstract description 9
- 239000002336 ribonucleotide Substances 0.000 abstract description 9
- 125000002652 ribonucleotide group Chemical group 0.000 abstract description 9
- 239000005547 deoxyribonucleotide Substances 0.000 abstract description 8
- 125000002637 deoxyribonucleotide group Chemical group 0.000 abstract description 8
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 7
- 108091033319 polynucleotide Proteins 0.000 abstract description 7
- 239000002157 polynucleotide Substances 0.000 abstract description 7
- 102000040430 polynucleotide Human genes 0.000 abstract description 7
- 229920000642 polymer Polymers 0.000 abstract description 6
- 230000004075 alteration Effects 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 20
- 238000002744 homologous recombination Methods 0.000 description 16
- 230000006801 homologous recombination Effects 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- 108091092562 ribozyme Proteins 0.000 description 10
- 102000053642 Catalytic RNA Human genes 0.000 description 9
- 108090000994 Catalytic RNA Proteins 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 7
- 238000004520 electroporation Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003471 mutagenic agent Substances 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 102000001218 Rec A Recombinases Human genes 0.000 description 5
- 108010055016 Rec A Recombinases Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- -1 nucleic acid compound Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000221566 Ustilago Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- PGSPUKDWUHBDKJ-UHFFFAOYSA-N 6,7-dihydro-3h-purin-2-amine Chemical compound C1NC(N)=NC2=C1NC=N2 PGSPUKDWUHBDKJ-UHFFFAOYSA-N 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 244000301083 Ustilago maydis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 1
- SRBFZHDQGSBBOR-QMKXCQHVSA-N alpha-L-arabinopyranose Chemical compound O[C@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-QMKXCQHVSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000010397 one-hybrid screening Methods 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Mycology (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及多核苷酸,它的第一链含有核糖核苷酸和脱氧核糖核苷酸两种,而第二链仅含有脱氧核糖核苷酸;其中链是Watson-Crick配对的并且通过寡核苷酸连接,如此该多核苷酸至多具有一个单一3′末端和一个单一5′末端。可将这些末端连接,这样多核苷酸就成为一个单一连续环状聚合物(single continuous circular polymer)。该多核苷酸可用于向靶基因中引入特定改变。
Description
本申请是于1993年12月9日递交的第08/164303号专利申请的后续申请,后者全文引入本文以供参考。
1.发明领域
本发明涉及分子遗传学领域。具体地说它涉及向活的、培养的真核细胞中引入特定基因改变的核酸化合物及其应用。更具体地说,它主要涉及基本上Watson-Crick配对的双链核酸,其中双链中的一条链的部分包含含2′-O或2′-OMe核糖的核苷酸,剩余部分包含脱氧核糖核苷酸。
2.发明背景
2.1.嵌合和/或杂种双链核酸
本发明领域涉及核酸。核酸是杂聚物,即不同亚单位的聚合物,亚单位是通过定向的磷酸二酯键或其衍生物连接形成聚合物。双链核酸是这样的核酸,按照尿嘧啶或胸腺嘧啶与腺嘌呤对应和胞嘧啶与鸟嘌呤对应的原则,双链中第一链的每一碱基对应于第二链的碱基。据说拥有这种对应性的逆平行双链是Watson-Crick配对的。双链核酸可有两种主要类型:核糖核酸和脱氧核糖核酸。每种核糖核苷酸都有相应的脱氧核糖核苷酸,例如,腺嘌呤和脱氧腺嘌呤,胞嘧啶和脱氧胞嘧啶,鸟嘌呤和脱氧鸟嘌呤,尿嘧啶和胸腺嘧啶。如本领域中所用的那样,在同一链中存在核糖核苷酸和脱氧核糖核苷酸的核酸被称为混合或嵌合(下文称“嵌合”)核酸。其中脱氧核糖核苷酸和核糖核苷酸相互对应的双链核酸被称为杂种双链(hybrid-duplex)。当两条链形成少于其全部碱基的双链核酸区时,所形成的分子被称为异形双链(heteroduplex)。
更经常地,双链核酸的两条链是非共价键合的,而仅通过Watson-Crick配对相连。然而,双链的两条链可通过寡核苷酸连接形成单一聚合物(single polymer)。连接寡核苷酸不是Watson-Crick配对的。其中第一链和第二链是单一聚合物的部分的异形双链被称为“发夹双链”或“柱和环”结构。本文采用前一种名称。
本文所用嵌合现象是核酸聚合物的一种特性,而杂种现象则是双链的一种特性。例如,mRNA及其模板形成杂种双链,但二者都是非嵌合的,然而例如嵌合的八核苷酸5′d(TTTT)-r(CCCC)3′和5′r(GGGG)-d(AAAA)3′相互形成Waston-Crick双链,但生成的双链是非杂种双链。下文称非杂种双链的双链核酸为“同质双链”(homo-duplex)。除非另外特别说明,同质双链仅指包含脱氧核苷酸的双链。最后,值得注意的是本领域中称Watson-Crick双链的形成为“杂交(hybridigation)”,即使其形成的是非杂种双链核酸。
对X射线衍射和二维NMR分析嵌合和/或杂种核酸结构的研究感兴趣的人们已合成了用于此研究的嵌合核酸和杂种双链核酸。参见,例如Salazar,M.等,1994,J.Mol.Biol.241:440-55和Egli,M.等,1993,Biochemistry 32:3221-37(r3d7.d10形式的双链的嵌合杂种双链);Ban,C.等,1994,J.Mol.Biol.236:275-85(d5r1d4形式的自身互补嵌合杂种双链);Chou,S.H.,1991,Biochemistry 30:5248-57(d4r4d4形式的自身互补和非自身互补的嵌合杂种双链)。这些双链核酸的互补链彼此是非共价键合的;它们仅通过Waston-Crick配对相连。
合成了嵌合核酸的第二组科学家感兴趣于核糖酶(ribozyme)的研究和用途,核糖酶即自身切开或切开其它RNA的RNA分子。Perreault,J.P.等,1990,Nature 344:565;Taylor,N.R.等,1992,Neucleic Acids Research20:4559-65;Shimaya,T.,1993,Nrucleic Acids Research 21:2605。这些研究发现嵌合核糖酶具有活性,并且对核酸酶的消化比RNA核糖酶具有更强的耐受性。嵌合核糖酶是自身互补的,即Waston-Crick配对链是共价连接的。在嵌合核糖酶的研究期间合成的化合物不同于上面提到的杂种双链分子,它们被合成用于结构的研究,因为其中的嵌合核糖酶不包括稳定的杂种双链。因而,具有DNA结合臂的嵌合核糖酶与其底物结合,并形成杂种双链。Yang,G.H.等,1990,Biochemistry 29:11156-60。还参见Sawata,S.等,1993,Neucleic Acids Research 21:5656-60;Hendry,P.等,1992,Neucleic Acids Research 20:5737-41;Shimayama,T.,1993,Neucleic Acids Research 21:2605。核糖酶催化RNA底物的切开,杂种双链因此溶解。
2.2.真核细胞中定点遗传改变
分子生物学领域的技术人员知道不仅经常需要向靶真核细胞中引入新的多核酸序列,即新的基因,而且也需要对靶细胞中确定的预先存在的基因加以改变。靶细胞可在培养物中使用或者使用它建立转基因动物。
已经建立了许多向培养的真核细胞中引入DNA的技术。这些技术包括磷酸钙沉淀法,DEAE-葡聚糖介导的胞吞作用,电穿孔,脂质体介导的融合,使用复制缺损病毒的转导作用。然而,这些技术虽然十分普遍地用于向真核细胞中引入功能性基因,但它们不能轻而易举地完成对特定存在基因的改变(突变)。引入之后,外源性DNA通过异常重组在细胞基因组中随机位点上分离,而不是通过同源重组在特定位点上分离。
迄今为止,还没有一种令人普遍满意的向高级真核细胞,即哺乳动物或鸟类细胞中引入定点或特异位点的遗传改变(诱变)的方案。虽然在真核细胞中通过引入极长(>1kb)的核酸可获得同源重组,但这些技术需要应用复杂的筛选技术,因为在高级真核细胞中异常重组率大大超过了同源重组率。Thomas,K.R.& Smithies,M.R.,1987,Cell 52:503。还参见Valancius,V.& Smithies,O.,1991,Mol.Cell.Biol.11:4389(比较真核细胞中线性化和超螺旋质粒的同源重组)。
一种完成优势定点诱变的方法是向细胞中直接引入单链寡脱氧核苷酸。这一技术被成功地用于酵母中,同源重组在啤酒酵母(Saccharomycescerevisiae)中的活性显著高于真核细胞。Moreschell,R.P.等,1988,Proc.Natl.Acad.Sci.85:524-28;Yamamoto,T.等,1992,Yeast 8:935-48。并且,至今也没有用单链寡核苷酸成功地转化哺乳动物或鸟类细胞的报道。
研究表明改变的嘌呤和嘧啶上碱基区,即〔d(TG)30·d(AC)30〕显示显示了令人喜悦的重组率,由此可推知哺乳动物中靶DNA结构和同源重组率之间的关系。对培养的哺乳动物细胞的非复制质粒的研究证实了这些效果。Wahls,W.P.等,1990,Mol.Cell.Biol.10:785-93。这些实验没有进而表明外源性核酸和细胞基因组之间的重组。
曾尝试使用RecA,一种促进细菌(大肠杆菌)中同源重组的蛋白质来促进真核细胞中的同源重组。但是,这些尝试显然未获得成功。例如,W.Bertling的美国专利4950599公开了在真核细胞中使用RecA导致极低的定向位点突变率,并且同源重组率也未增高。D.Zarling和E.Sane的专利申请WO93/22443及D.C.Gruenert和Z.Kunzelmann的申请94/04032都旨在校正培养的涉及囊纤维变性的细胞系中的基因缺损。这些出版物公开了证实原理的原始实验数据而非涉及操作方法实施例的数据。为将多核苷酸/RecA复合物引入到核中,Zarling和Gruenert使用膜是通透性的细胞,尽管这类细胞不能进一步生长。另外,即使这些出版物宣称在完整细胞中发生了RecA促进同源重组,它们也未给出对其频率的定量评价。因此,还没有证据可令人信服地表明在任何活的真核细胞中,使用原核RecA导致的同源重组率明显高于自发性同源重组率。
3.发明概述
本发明涉及单一共价连接的双链寡核苷酸,它与所研究的基因同源,且具有脱氧核糖核苷酸和核糖核苷酸。为了产生遗传改变,在同源区内,有一对或多对非对应(下文称“异源”或“突变基因”)碱基对。通常,细胞原有的同源重组过程导致突变基因核苷酸***靶基因组位置。可使用本发明的双链寡核苷酸(下文称“嵌合载体”)向基因中引入异源碱基对,特定地改变所研究的基因。异源碱基对可能是不同于所研究的基因的碱基对,或者可能是所研究基因中存在的碱基对之外那些碱基对(***),或者异源碱基对还可能是不存在于所研究基因中的碱基对(缺失)。本发明部分地是基于下述发现,即载体中包含杂种双链核酸的约15-50个碱基对区大大提高所研究基因的改变率。当异源碱基对区是1-50个碱基对时,异源碱基对可以同质或杂种双链存在于本发明的载体中。当异源碱基对长度大于50个碱基对时,它优选以同质双链存在。
可采用任何已知的向真核细胞中引入核酸的方法向靶细胞中引入载体。虽然就理论而言没有限定,但据信嵌合载体是通过靶细胞的重组/修复机制来参与的,并且经基因转化或同源重组指导靶基因改变。
4.附图的简要说明
图1显示图表表示的两种嵌合载体。特定标记如下:1,第一链;2,第二链;3,异源区;4,同质区;5,连接物;6,连接位点。
图1A是R-D-R形式的连接的嵌合载体。
图1B是R-D-R形式的具有单一3′和5′末端的发夹式嵌合载体。
5.发明详述
5.1.本发明嵌合载体的描述
本发明包括含有含脱氧核糖和核糖的碱基双链核酸。因此它们包括DNA和RNA区,故而被称为“嵌合载体”。嵌合载体的核糖核苷酸的2′-O可以是甲基化的。任何磷酸二酯都可被硫代磷酸二酯或甲基磷酸二酯替代。
本发明的嵌合载体是单一核酸聚合物。因此本发明的嵌合载体须至少包括1个碱基至更通常的3或4个碱基,这些碱基不是Watson-Crick配对的。这些未配对碱基区连接两条Waston-Crick配对的碱基链。与其它合成的具有未配对核苷酸的嵌合核苷酸相反嵌合载体没有酶活性,即它们不催化化学反应或者在没有生物能源,如ATP存在下它们自身进行化学反应。
优选实施方案中的连接区碱基是脱氧核糖核苷酸。可构建具有两个连接区的嵌合载体,以使聚合物的3′和5′末端与相邻的互补链核苷酸呈Waston-Crick配对。它们易于连接使嵌合载体形成单一连续环状核酸聚合物。
基本上,嵌合载体的所有其余碱基都是Waston-crick配对的。本文所描述的碱基是Waston-Crick配对的或它们形成双链核酸应被理解为在适当的温度和盐的条件下,它们可形成碱基对或双链核酸。应该知道在某些少盐和/或升高的温度条件下,Waston-crick碱基对会失去热力学稳定性而使得双链核酸熔解掉或变性。还应知道一或两对碱基对失配并不影响本发明的可操作性。
本发明的嵌合载体旨在将改变(突变)特定地引入靶基因。通过选择具有与靶位点序列相同(同源)序列的嵌合载体部分(下文称之为同源区)确定遗传改变位点。嵌合载体序列和靶基因之间的不同区被称为异源区。应注意到嵌合载体与靶基因虽是异源的,但在该载体区中并不是异形双链。根据本发明的优选实施方案,每个嵌合载体有两个同源区,它们位于***的异源区侧翼,所有这三个区都以单一连续双链核酸形式存在。再有,依据本发明,每个同源区包括杂种双链核酸部分。每个杂种双链至少是4对碱基对,优选为8对碱基对,更优选为约20-30对碱基对。嵌合载体的作用并不受到杂种双链区内同质双链的二核苷酸碱基对的影响,置入嵌合载体使3′和5′末端彼此连接。两个同源区的长度至少为20对碱基对,优选在40-60对碱基对之间。
依据本发明,可将同质双链核酸区排列在载体的杂种双链/同源区之间。被***的同质双链区可包括异源区。当异源区少于约50对碱基对,优选地少于约20对碱基对时,可存在或不存在被***的同质双链区。当异源区超过约20对碱基对时,包含异源区的被***同质双链是优选的。
5.2.本发明的嵌合载体的构建
可使用任意方法合成本发明的嵌合载体。使用经改进的用于DNA固相合成的技术可最简便地合成嵌合载体。参见Caruthers,M.H.,1985,Science 230:281-85;Itakura,K.等,1984,Ann.Rev.Biochem.53:523-56。可合成RNA和嵌合核酸的改进方法公开于Scaringe,S.A.等,1990,NucleicAcids Research 18:5433-41;Usman,N.等,1992,Nucleic Acids Research20:6695-99;和Swiderski,P.M.等,1994,Anal.Biochem.216:83-88,上述文献均全文引入本文以供参考。有关嵌合核酸合成的新近进展综述于Usman,N.& Cedergren,R.,1992,Trends Bioch.Sci.17:334-9。
***两个杂种双链区之间的包含同质双链区的嵌合载体可使用半合成技术来建立。构建两种合成的具发夹构象的嵌合多聚核酸。使用与两种不同限制酶的消化产物的重叠部分互补的重叠交叉末端,构建两种嵌合核酸的游离3′和5′末端。得到与限制酶消化末端互补的同质双链区。可采用本领域技术人员熟知的技术来完成限制酶位点与克隆DNA片段末端的加成,所述技术例如,但不限于使用伸展引物的PCR扩增和包含限制位点的连接体的平整末端连接。可使用常规的酶促技术连接两种嵌合核苷酸和同质双链区。通过在Tris Borate EDTA缓冲液中的6%聚丙烯酰胺电泳从不完全反应的底物中分离两个末端连接的嵌合寡核苷酸。该线性加帽的分子是压缩的并且在这一条件下的电泳更缓慢。
仅含有天然产生的核苷酸的嵌合载体也可用于本发明。据发现包含约20个核糖核苷酸的杂种双链区的嵌合载体在体外是RNAse H抗性的。可通过用2′-O甲基化核糖核苷酸替代核糖核苷酸获得对酶促降解的抗性。另外或者可选择性地,核酸的磷酸二酯键可被硫代磷酸二酯键替代。Shimayama,T.等,1993,Nucleic Acids Research 21:2605.也可以使用含***糖的核苷酸。本文所用术语核酸意指包括带有这些修饰的核酸。
5.3.本发明的嵌合载体的应用
本发明的嵌合载体可用于靶细胞基因组的特定位置上的突变。采用其核酸序列定义靶位的特定位置,下文中称此核酸序列为靶序。依据本发明构建嵌合载体,其中除存在某些杂种双链区外,同源区与靶序列一致。异源区编码被引入的变化。变化可是序列的一个或多个碱基变化或者是一个或多个碱基的加成。当靶序列的变化是少于约20个碱基的加成时,可采用一或二个杂种双链区实现本发明。当靶序列的变化是多于约50个碱基的加成时,则优选采用被包括在同质双链区内的异源区。
本发明的实现要求向靶细胞核中引入嵌合载体。任何导致这种引入的方法均可使用。这类方法包括电穿孔法,DEAE葡聚糖法,磷酸钙沉淀法,脂质体介导的融合法(LIPOFECTIN)和直接注射法。电穿孔法是特别适合的。
在本发明的一个实施方案中嵌合载体用于建立转基因动物。按照文献描述方法,采用直接注射法向***的原核中引入嵌合载体,所述文献是Brinster R.L.等,1989,PROC.NATL.ACAD.SCI.86:7087;还有T.E.Wagner和P.C.Hoppe的美国专利4,873,191,二者都全文引入本文以供参考。另外,可向胚胎干细胞中引入嵌合载体,可用正常胚泡细胞聚集胚胎干细胞从而产生嵌合动物,以嵌合动物的后代可重新获得转基因动物,该方法参见Capccchi,M.R.,1989,Science 244:1288,该文献全文引入本文以供参考。
采用电穿孔法,每10,000个被处理细胞就有一个细胞在靶序列上发生特异性突变(下文称“转化”)。因此,本发明的实践包括从大量未突变细胞中选择转化细胞的方法的使用。在另一个实施方案中,转化细胞的优点增多。这些增多的优点的非限制性实例包括抗药性,生长调节的改变和利用代谢物能力的改变。在另一个实施例中,选择方法是负选择法,使用该方法在所选择条件下使得被转化细胞不能生长,并且通过使其暴露在选择性破坏增殖细胞的条件下而除去未被转化的细胞。
另外,被转化的细胞可具有改变的细胞表面抗原表型,它可通过免疫荧光进行检测,采用荧光激活细胞分离器进行选择。
当向细胞中引入嵌合载体的方法是直接注射法时,例如当采用原核注射法建立转基因动物时,每10,000个细胞的转化率可高于1个细胞。因此,大大降低了选择的需要。
采用电穿孔法转化的嵌合载体的典型用量是每百万个培养细胞在10-1000ng之间。
6.实施例
6.1.实施例1:对黑粉菌属真菌的体内活性
野生型黑粉菌具有功能性的尿嘧啶(ura)-3基因,其产物是尿嘧啶生物合成途径中的一部分。当野生型黑粉菌生长于5′-fluororotic acid(5FOA)培养基中时,细胞由于该酸加入到上述途径中而死亡。假如尿嘧啶-3发生突变,则不会产生尿嘧啶-3mRNA,细胞就得以在5FOA培养基中存活。
内源性尿嘧啶-3基因序列是本领域中已知的。在一组实验中,该序列的碱基358由腺嘌呤变为胸腺嘧啶,这一突变导致功能障碍蛋白的产生。
嵌合载体的合成如下:
碱基358突变的载体:(358 RNA载体)
5′TGCCGATCGGCAACTTTTGUUGCCGAUCGGCAAATTT 3′(SEQ ID:1)
该358载体采用发夹构象。划线碱基表示核糖核酸残基。黑体字母表示突变基因(异型区)。斜体"T"表示未配对碱基。
建立具有相同序列但不包含核糖核酸的载体作为对照。在该载体中胸腺嘧啶被尿嘧啶替代。
对照载体在碱基358进行突变:(DNA 358载体)
5′TGCCGATCGGCAACTTTTGTTGCCGATCGGCAAATTT 3′
(SEQ ID:2)也采用发夹构象。再者,黑体残基是突变基因。
进行体内转化实验,按照本领域所熟知的方法,将U.maydis细胞制成回收率为50ul转化缓冲液中106个细胞的原生质体,并使用不同量的嵌合载体进行转染或者将同源(仅DNA)载体与原生质体在37℃混合。然后,将细胞铺于所选择的培养基上,计数存活菌落(转化细胞)的数目。结果以下面的表格形式表示:
转染数量(ug) | 载体-358类型 | 存活菌落数 |
0.1 | DNA | 0 |
0.1 | 嵌合的 | 13 |
0.25 | DNA | 1 |
0.25 | 嵌合的 | 49 |
0.75 | DNA | 12 |
0.75 | 嵌合的 | 131 |
1.0 | DNA | 19 |
1.0 | 嵌合的 | 573 |
这些数据表明使用RNA 358载体的细胞转染与使用相应DNA载体的转染相比,极大地提高了细胞的存活率。
6.2.实施例2:NIH 3T3细胞的转化
NIH 3T3细胞是具有良性(可控制的)生长特性的人细胞。恶性(无控制的)生长特性是由致癌基因H→ras中的单位点突变给予的,所谓突变是由Thr替代Gly12。这样,G→T12导致生长特性的易于选择的变化。Taparowsky,E.等,1982,Nature 300:762;Sukumar S.等,1983,Nature306:658。
建立下述序列以指导发生G→T12突变的嵌合载体:5′-CACACCGACGGCGCCCACCACTTTGTGGTGGGCGCCGTCGGTGTGGGTTTGCC-3′(SEQ ID:3)
该序列以常规单字母代码表示,其它特点是未划线的表示RNA,未配对碱基是斜体,突变体碱基是黑体。需要注意的是,环化之后通过两个三胸腺嘧啶序列将嵌合载体分为两条基本上互补的链,并且所有含核糖的核苷酸仅存在于两条链中的一条。
使用2′-OMe核糖碱基合成两种形式的嵌合载体,它们分别具有一个("R")和两个("R-D-R")的翼侧有四个脱氧核糖残基的杂种双链区。R-D-R形式如上SEQ ID:3所示,R形式除碱基6-9是脱氧核苷酸外是相同的。值得注意的是,5′和3′末端是脱氧核苷酸。采用如在重组DNA中常用的相同DNA连接酶法,在合成之后环化嵌合载体。连接之后,通过两次重复的制备性D600凝胶(AT Biochem,Malvern,PA)电泳从底物中分离环化嵌合载体。
对照载体是:1)没有杂种双链的相同序列(“同质双链”
所示数据);2)具有5′-GCCCACACCGACGGCGCCACCAC-3′(SEQ ID 4)序列的未配对DNA(“sDNA”所示数据);3)没有异源区的嵌合载体,因而是没有突变基因的核苷酸(未显示数据)。
采用电穿孔法通过转化NIH 3T3细胞(1×106个细胞)进行实验。电穿孔法之后,将细胞以4×103个接种密度铺于培养基中并使其生长14天。用结晶紫染色灶形成细胞使转化细胞可见。使用编码T12形式的H ras的质粒pT24作为阳性对照。该对照用于测定转染的NIH 3T3细胞中的异常重组水平。该实验重复5次,下表表示其概括性结果。除下面所示结果外,使用没有突变基因密码子的嵌合载体的对照实验未显示出NIH 3T3细胞转化灶。
载体类型 | 转染量(每106个细胞) | 转化细胞每106个细胞(14天) |
pT24(阳性对照) | 10ug | 57 |
sDNA | 1ug | 2 |
sDNA | 10ug | 13 |
同质双链 | 1ug | 0 |
同质双链 | 10ug | 2 |
嵌合的 | 50ng | R-D-R R19 12 |
嵌合的 | 200ng | 55 43 |
嵌合的 | 1ug | 139 103 |
这些结果表明嵌合载体通过同源重组引入特定突变以转化哺乳动物细胞。该实验中的转化率大大高于通过异常重组的转化率,这是由使用包含完全突变的H-ras基因的pT24阳性对照载体进行转染观察到的。因此,在哺乳动物细胞中使用嵌合载体的同源重组率远远高于异常重组率。
序列表
(1)普通信息:
(i)申请者:Kmiec,Eric
(ii)发明题目:用于真核细胞中定点突变的化合物和方法
(iii)序列数:4
(iv)通讯地址:
(A)收信人:Pennie & Edmonds
(B)街道:1155 Avenue of the Americas
(C)城市:New York
(D)国家:NY
(F)邮政编码:10036-2731
(V)可读计算机源:
(A)媒介类型:软盘
(B)计算机:IBM PC兼容机
(C)操作***:PC-DOS/MS-DOS
(D)软件:PatentIn Release #1.0,Version #1.25
(vi)当前申请资料:
(A)申请号:US
(B)递交日:
(C)分类:
(viii)律师/代理人信息:
(A)姓名:Friebel,Thomas E.
(B)注册号:29,258
(C)文献/摘要号:7991-009
(ix)通讯信息:
(A)电话:(212)790-9090
(B)传真:(212)869-8864/009(2)第一序列(SEQ ID:1)信息:(i)序列特征:(A)长度:37对碱基对(B)类型:核酸(C)链合方式:自身互补(D)拓扑结构:线性(ii)分子类型:DNA/RNA(ix)特点:(A)名称/检索表:-(B)位点:19..32(D)其它信息:/标记=a/注="RNA"(xi)序列描述:第一序列描述:TGCCGATCGG CAACTTTTGU UGCCGAUCGG CAAATTT 37(2)第二序列(SEQ ID:2)信息:(i)序列特征:(A)长度:37对碱基对(B)类型:核酸(C)链合方式:自身互补(D)拓扑结构:线性(ii)分子类型:DNA(xi)序列描述:第二序列描述:TGCCGATCGG CAACTTTTGT TGCCGATCGG CAAATTT 37(2)第三序列(SEQ ID:3)信息:(i)序列特征:(A)长度:53对碱基对(B)类型:核酸(C)链合方式:自身互补(D)拓扑结构:线性(ii)分子类型:DNA/RNA(ix)特点:(A)名称/检索表:-(B)位点:2..5(D)其它信息:/标记=b/注="RNA"(ix)特点:(A)名称/检索表:(B)位点:10..21(D)其它信息:/标记=d/注=“RNA”(ix)特点:(A)名称/检索表:(B)位点:51..52(D)其它信息:/标记=f/注=“RNA”(xi)序列描述:第三序列描述:CACACCGACG GCGCCCACCA CTTTGTGGTG GGCGCCGTCG GTGTGGGTTT GCC 53(2)第四序列(SEQ ID:4)信息:(i)序列特征:(A)长度:23对碱基对(B)类型:核酸(C)链合方式:自身互补(D)拓扑结构:线性(ii)分子类型:DNA(xi)序列描述:第四序列描述:GCCCACACCG ACGGCCCCAC CAC 23
Claims (17)
1.一种至多具有一个3′末端和一个5′末端的嵌合核酸,该核酸还包含:
a.邻接排列的未配对碱基区,这样未配对区将核酸分为第一链和第二链;
b.长度至少为15对碱基对的Watson-Crick配对的核酸区,其中,第一链的碱基对应于第二链的碱基,以及其中;
c.第一链包含至少三个邻接的由2′-O或2′-OMe核糖组成的核苷酸区,在杂种双链(hybrid-duplex)中它们是Watson-Crick配对的。
2.权利要求1的核酸,其中第二链不包含由2′-O或2′-OMe核糖组成的核苷酸。
3.权利要求2的核酸,其中杂种双链至少包含9个邻接的由2′-O核糖组成的核苷酸,其翼侧为由2′-脱氧核糖组成的核苷酸。
4.权利要求2的核酸,其中第一链包含两个邻接的由2′-O或2′-OMe核糖组成的核苷酸区,它们形成两个杂种双链区,每个杂种双链区的长度至少为4对碱基对,并且同质双链(homo-duplex)***区排列于两个杂种双链区之间,该***区为至少1对碱基对。
5.权利要求2的核酸,其中第一链包含两个由2′-O或2′-OMe核糖组成的核苷酸区,它们形成两个杂种双链区,每个杂种双链区的长度至少为8对碱基对,并且同质双链***区排列于两个杂种双链区之间,该***区为至少4对碱基对。
6.权利要求5的核酸,其中同质双链***区由4-50对2′-脱氧核糖碱基对组成。
7.权利要求5的核酸,其中同质双链***区由30-1,000对2′-脱氧核糖碱基对组成。
8.权利要求2的核酸,其中5′和3′末端是连接的。
9.权利要求5的核酸,其中5′和3′末端是连接的。
10.权利要求6的核酸,其中5′和3′末端是连接的。
11.权利要求7的核酸,其中5′和3′末端是连接的。
12.一种将预定改变引入有核细胞基因组的靶序列中的方法,它包括下述步骤:
a.提供一种嵌合载体,它具有两个靶序列同源区,和一个排列在两个同源区之间的编码这种改变的异源区;
b.使嵌合载体保持在细胞核中,以使嵌合载体与靶序列发生遗传学重组。
13.权利要求12的方法,其中核是卵的原核并且采用直接注射法引入。
14.权利要求12的方法,其中核是胚胎干细胞核并且采用直接注射法引入。
15.一种获得改变特征的细胞群的方法,它包括下述步骤:
a.提供一种嵌合载体,它具有两个靶序列同源区,和一个排列在两个同源区之间的编码这种改变的异源区;
b.使嵌合载体保持在细胞核中,由此嵌合载体与靶序列发生重组,细胞被转化;及
c.选择转化细胞。
16.权利要求15的方法,其中细胞是哺乳动物细胞。
17.权利要求15的方法,其中细胞是酵母菌或真菌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16430393A | 1993-12-09 | 1993-12-09 | |
US08/164,303 | 1993-12-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98118786A Division CN1117866C (zh) | 1993-12-09 | 1998-08-22 | 将预定改变引入有核细胞基因组的靶序列中的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1142829A true CN1142829A (zh) | 1997-02-12 |
CN1048254C CN1048254C (zh) | 2000-01-12 |
Family
ID=22593886
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94194935A Expired - Fee Related CN1048254C (zh) | 1993-12-09 | 1994-12-09 | 用于将预定的改变引入靶基因中的化合物 |
CN98118786A Expired - Fee Related CN1117866C (zh) | 1993-12-09 | 1998-08-22 | 将预定改变引入有核细胞基因组的靶序列中的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98118786A Expired - Fee Related CN1117866C (zh) | 1993-12-09 | 1998-08-22 | 将预定改变引入有核细胞基因组的靶序列中的方法 |
Country Status (15)
Country | Link |
---|---|
US (3) | US5565350A (zh) |
EP (1) | EP0733059B1 (zh) |
JP (1) | JP3585238B2 (zh) |
KR (1) | KR100386337B1 (zh) |
CN (2) | CN1048254C (zh) |
AT (1) | ATE196311T1 (zh) |
AU (1) | AU691550B2 (zh) |
CA (1) | CA2178729A1 (zh) |
DE (2) | DE69425903T2 (zh) |
DK (1) | DK0733059T3 (zh) |
ES (1) | ES2149962T3 (zh) |
GR (1) | GR3034988T3 (zh) |
NZ (1) | NZ278490A (zh) |
PT (1) | PT733059E (zh) |
WO (1) | WO1995015972A1 (zh) |
Families Citing this family (793)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6475795B1 (en) * | 1991-07-03 | 2002-11-05 | Meditech Research, Ltd. | Use of hyaluronan in gene therapy |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
US20020108136A1 (en) * | 1997-03-21 | 2002-08-08 | Sri | Transgenic animals produced by homologous sequence targeting |
US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
AU679566B2 (en) | 1993-09-03 | 1997-07-03 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
US5731181A (en) * | 1996-06-17 | 1998-03-24 | Thomas Jefferson University | Chimeric mutational vectors having non-natural nucleotides |
US5760012A (en) * | 1996-05-01 | 1998-06-02 | Thomas Jefferson University | Methods and compounds for curing diseases caused by mutations |
US9096636B2 (en) * | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20030044941A1 (en) | 1996-06-06 | 2003-03-06 | Crooke Stanley T. | Human RNase III and compositions and uses thereof |
ATE264864T1 (de) * | 1997-03-03 | 2004-05-15 | Applera Corp | Verbesserte chimäre oligonukleotidvektoren |
US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
GB9711015D0 (en) * | 1997-05-28 | 1997-07-23 | Zeneca Ltd | Improvements in or relating to organic compounds |
ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
CN100419083C (zh) * | 1997-08-05 | 2008-09-17 | 金默拉根有限公司 | 用混合双链寡核苷酸在植物中实现定点遗传改变的用途 |
US7102055B1 (en) * | 1997-11-18 | 2006-09-05 | Pioneer Hi-Bred International, Inc. | Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant |
NZ503859A (en) * | 1997-11-18 | 2003-02-28 | Pioneer Hi Bred Int | Non-identical minimal recombination sites (FRT) which are non-identical for targeted integration of nucleotide sequences into transformed plants |
CA2309719A1 (en) | 1997-11-18 | 1999-05-27 | Pioneer Hi-Bred International, Inc. | Targeted manipulation of genes in plants |
EP0945507A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Mannheim Gmbh | Tumorspezifische Expressionskontrollregion und deren Verwendung |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
US6004804A (en) * | 1998-05-12 | 1999-12-21 | Kimeragen, Inc. | Non-chimeric mutational vectors |
US6010907A (en) | 1998-05-12 | 2000-01-04 | Kimeragen, Inc. | Eukaryotic use of non-chimeric mutational vectors |
EP1080103A4 (en) * | 1998-05-21 | 2003-07-02 | Isis Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR NON-PARENTERAL ADMINISTRATION OF OLIGONUCLEOTIDES |
CA2329252A1 (en) | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals Inc. | Compositions and methods for topical delivery of oligonucleotides |
US6693185B2 (en) | 1998-07-17 | 2004-02-17 | Bayer Bioscience N.V. | Methods and means to modulate programmed cell death in eukaryotic cells |
DE19836098A1 (de) | 1998-07-31 | 2000-02-03 | Hoechst Schering Agrevo Gmbh | Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zur Herstellung der Pflanzen, ihre Verwendung sowie die modifizierte Stärke |
CA2344653A1 (en) | 1998-09-29 | 2000-04-06 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
AU773808B2 (en) | 1998-11-09 | 2004-06-10 | Bayer Cropscience Aktiengesellschaft | Nucleic acid molecules from rice and their use for the production of modified starch |
US6438561B1 (en) * | 1998-11-19 | 2002-08-20 | Navigation Technologies Corp. | Method and system for using real-time traffic broadcasts with navigation systems |
US6917882B2 (en) | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
WO2000042559A1 (en) * | 1999-01-18 | 2000-07-20 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
US20030054390A1 (en) * | 1999-01-19 | 2003-03-20 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
DE60044223D1 (de) | 1999-01-19 | 2010-06-02 | Maxygen Inc | Durch oligonukleotide-vermittelte nukleinsäuren-rekombination |
US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6127124A (en) * | 1999-01-20 | 2000-10-03 | Isis Pharmaceuticals, Inc. | Fluorescence based nuclease assay |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
CA2368655A1 (en) * | 1999-04-08 | 2000-10-19 | Gregory M. Glenn | Dry formulation for transcutaneous immunization |
CA2370132C (en) | 1999-05-07 | 2012-01-24 | E. I. Du Pont De Nemours And Company | Auxin transport proteins |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6271360B1 (en) | 1999-08-27 | 2001-08-07 | Valigen (Us), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
CA2389441A1 (en) | 1999-10-07 | 2001-04-12 | Valigen, Inc. | Compositions and methods for plant genetic modification |
AR025996A1 (es) | 1999-10-07 | 2002-12-26 | Valigen Us Inc | Plantas no transgenicas resistentes a los herbicidas. |
US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
US20030190644A1 (en) | 1999-10-13 | 2003-10-09 | Andreas Braun | Methods for generating databases and databases for identifying polymorphic genetic markers |
US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
US7820878B2 (en) * | 1999-11-19 | 2010-10-26 | Kyowa Hakko Kirin Co., Ltd. | Production of ungulates, preferably bovines that produce human immunoglobulins |
AU1777301A (en) * | 1999-11-19 | 2001-05-30 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
US7074983B2 (en) * | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20060134629A1 (en) * | 2000-03-20 | 2006-06-22 | Link Charles J | Methods and compositions for elucidating protein expression profiles in cells |
US6897020B2 (en) * | 2000-03-20 | 2005-05-24 | Newlink Genetics Inc. | Methods and compositions for elucidating relative protein expression levels in cells |
OA12240A (en) * | 2000-03-27 | 2006-05-10 | Univ Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides. |
US6936467B2 (en) * | 2000-03-27 | 2005-08-30 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
WO2001087914A2 (en) * | 2000-05-17 | 2001-11-22 | University Of Delaware | Plant gene targeting using oligonucleotides |
US6686188B2 (en) * | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
US6656700B2 (en) * | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
WO2001094610A2 (en) * | 2000-06-05 | 2001-12-13 | Thomas Jefferson University | Binary hybrid mutational vectors |
US7468475B2 (en) | 2000-06-16 | 2008-12-23 | Schmuelling Thomas | Method for modifying plant morphology, biochemistry and physiology |
US6958214B2 (en) | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
CA2417344A1 (en) * | 2000-07-27 | 2002-02-07 | University Of Delaware | Methods for enhancing targeted gene alteration using oligonucleotides |
US6875907B2 (en) | 2000-09-13 | 2005-04-05 | Pioneer Hi-Bred International, Inc. | Antimicrobial peptides and methods of use |
US20020119570A1 (en) * | 2000-09-25 | 2002-08-29 | Kyonggeun Yoon | Targeted gene correction by single-stranded oligodeoxynucleotides |
US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
US7560622B2 (en) | 2000-10-06 | 2009-07-14 | Pioneer Hi-Bred International, Inc. | Methods and compositions relating to the generation of partially transgenic organisms |
US7491534B2 (en) | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
US20020142397A1 (en) * | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
AU2002232858B2 (en) * | 2000-12-22 | 2007-01-11 | Sab, Llc | Methods for cloning mammals using reprogrammed donor chromatin or donor cells |
WO2002059337A1 (en) * | 2001-01-26 | 2002-08-01 | Georgetown University School Of Medicine | Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof |
AU2002303176A1 (en) * | 2001-03-27 | 2002-10-15 | University Of Delaware | Genomics applications for modified oligonucleotides |
AU2002303261A1 (en) * | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
WO2002081642A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
AU2002305151A1 (en) * | 2001-04-06 | 2002-10-21 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
WO2002081640A2 (en) * | 2001-04-06 | 2002-10-17 | Georgetown University | Gene shinc-1 and diagnostic and therapeutic uses thereof |
US20030045830A1 (en) * | 2001-04-17 | 2003-03-06 | De Bizemont Therese | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
US20040063922A1 (en) * | 2001-04-17 | 2004-04-01 | Conrad Charles A. | Methods and compositions for catalytic DNA exchange in a sequence specific manner |
US7053195B1 (en) | 2001-06-12 | 2006-05-30 | Syngenta Participatious Ag | Locked nucleic acid containing heteropolymers and related methods |
US20030148408A1 (en) | 2001-09-18 | 2003-08-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
KR100576674B1 (ko) | 2001-06-20 | 2006-05-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
WO2003000707A2 (en) | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
EP1925672A1 (en) | 2001-06-22 | 2008-05-28 | Syngeta Participations AG | Abiotic stress responsive polynucleotides and polypeptides |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
AU2002326589B2 (en) * | 2001-08-07 | 2008-06-05 | University Of Delaware | Compositions and methods for the prevention and treatment of Huntington's disease |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
US20030084473A1 (en) * | 2001-08-09 | 2003-05-01 | Valigen | Non-transgenic herbicide resistant plants |
US7456335B2 (en) * | 2001-09-03 | 2008-11-25 | Basf Plant Science Gmbh | Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants |
EP1427856B1 (en) | 2001-09-18 | 2011-05-11 | Carnegie Institution Of Washington | Fusion proteins useful for detecting analytes |
WO2003027264A2 (en) * | 2001-09-27 | 2003-04-03 | University Of Delaware | Coisogenic eukaryotic cell collections |
MXPA04002817A (es) | 2001-09-27 | 2004-07-05 | Pioneer Hi Bred Int | Polinucleotidos de fitato y metodos de uso. |
AU2002341905A2 (en) * | 2001-09-27 | 2003-04-07 | University Of Delaware | Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration |
US7468244B2 (en) * | 2001-09-27 | 2008-12-23 | University Of Delaware | Polymorphism detection and separation |
NZ566396A (en) | 2001-10-09 | 2009-07-31 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expressions |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
KR100801388B1 (ko) | 2002-01-02 | 2008-02-05 | 제넨테크, 인크. | 종양의 진단 및 치료 방법 및 이를 위한 조성물 |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
ATE508188T1 (de) | 2002-02-01 | 2011-05-15 | Life Technologies Corp | Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit |
US7135326B2 (en) * | 2002-02-07 | 2006-11-14 | E. I. Du Pont De Nemours And Company | UDP-glucosyltransferases |
WO2003069984A2 (en) | 2002-02-20 | 2003-08-28 | American Integrated Biologics, Inc. | Transgenic production in saliva |
US7566535B2 (en) * | 2002-03-07 | 2009-07-28 | University Of Delaware | Enhanced oligonucleotide-mediated nucleic acid sequence alteration |
AU2003233489B2 (en) | 2002-04-08 | 2008-10-02 | Pioneer Hi-Bred International, Inc. | Enhanced silk exsertion under stress |
US7244565B2 (en) * | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
US7138512B2 (en) * | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
MXPA04010092A (es) | 2002-04-16 | 2004-12-13 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
WO2003093296A2 (en) | 2002-05-03 | 2003-11-13 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof, and related methods |
CN1653174A (zh) | 2002-05-08 | 2005-08-10 | 巴斯福植物科学有限公司 | 用于提高植物含油量的方法 |
US20030228317A1 (en) * | 2002-05-22 | 2003-12-11 | Prafulla Gokhale | Gene BRCC-1 and diagnostic and therapeutic uses thereof |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US20030228558A1 (en) * | 2002-06-11 | 2003-12-11 | Bloom William Dennis | Method of training brokers in a multi-level marketing business |
US20050221326A1 (en) * | 2002-06-12 | 2005-10-06 | Avi Orr-Urtreger | Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto |
US20060258602A1 (en) * | 2002-09-20 | 2006-11-16 | Yukio Ando | Site-specific gene conversion promoter and gene therapeutic |
AU2003278957A1 (en) | 2002-09-26 | 2004-04-23 | Amgen, Inc. | Modulation of forkhead box o1a expression |
AU2003282477A1 (en) * | 2002-10-07 | 2004-05-04 | Napro Bio Therapeutics, Inc. | Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration |
US9150606B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
EP1560839A4 (en) | 2002-11-05 | 2008-04-23 | Isis Pharmaceuticals Inc | CHIMERIC OLIGOMER COMPOUNDS AND THEIR USE IN GENE MODULATION |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
BR0315300A (pt) * | 2002-11-08 | 2005-08-30 | Hematech Llc | Ungulados transgênicos tendo atividade de proteìna priÈnica reduzida e seus usos |
EP1569695B1 (en) | 2002-11-13 | 2013-05-15 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
ES2417879T3 (es) | 2002-11-13 | 2013-08-09 | Genzyme Corporation | Modulación antisentido de la expresión de la apolipoproteína B |
EP1572971B1 (en) | 2002-11-15 | 2009-09-30 | Morphotek Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
PT1578973E (pt) | 2002-12-19 | 2008-10-16 | Bayer Cropscience Ag | Células de plantas e plantas que sintetizam um amido com uma melhor viscosidade final |
NZ541637A (en) | 2003-02-11 | 2008-07-31 | Antisense Therapeutics Pty Ltd | Modulation of insulin like growth factor I receptor |
WO2004074440A2 (en) | 2003-02-17 | 2004-09-02 | Metanomics Gmbh | Preparation of organisms with faster growth and/or higher yield |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
EP1613746B1 (de) | 2003-03-31 | 2013-03-06 | University Of Bristol | Neue pflanzliche acyltransferasen spezifisch für langkettige, mehrfach ungesättigte fettsäuren |
US20040205840A1 (en) * | 2003-04-11 | 2004-10-14 | Pioneer Hi-Bred International, Inc. | Method for reducing gene expression |
ATE514781T1 (de) | 2003-04-15 | 2011-07-15 | Basf Plant Science Gmbh | Nukleinsäuresequenzen, die für proteine in zusammenhang mit abiotischer stressreaktion kodieren, sowie pflanzenzellen und pflanzen mit erhöhter umweltstressverträglichkeit |
WO2005014828A2 (en) | 2003-08-01 | 2005-02-17 | Basf Plant Science Gmbh | Process for the production of fine chemicals in plants |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
CA2524495A1 (en) | 2003-06-03 | 2005-01-13 | Eli Lilly And Company | Modulation of survivin expression |
US7790691B2 (en) * | 2003-06-20 | 2010-09-07 | Isis Pharmaceuticals, Inc. | Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
EP2166090B1 (de) | 2003-08-01 | 2015-07-01 | BASF Plant Science GmbH | Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenen Organismen |
PT1654276E (pt) | 2003-08-11 | 2013-03-25 | Kweek En Researchbed Agrico Bv | Plantas resistentes a fungos e seus usos |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
PE20050469A1 (es) | 2003-09-18 | 2005-09-10 | Lilly Co Eli | Modulacion de la expresion de eif4e |
WO2005027962A1 (en) | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
DK1678194T3 (da) | 2003-10-10 | 2013-10-07 | Alchemia Oncology Pty Ltd | Modulering af syntese og degradering af hyaluronan i behandlingen af sygdom |
EP2305798A3 (en) | 2003-10-23 | 2011-04-20 | Illumigen Biosciences, Inc. | Detection of mutations in a gene associated with resistance to viral infection, OAS1 |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
PT2161283E (pt) | 2003-11-17 | 2014-08-29 | Genentech Inc | Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética |
US20050120397A1 (en) * | 2003-11-24 | 2005-06-02 | Hermann Steller | Compounds and methods for regulation of spermatid differentiation |
MXPA06006998A (es) | 2003-12-17 | 2007-04-17 | Cropdesign Nv | Plantas que tienen caracteristicas de crecimiento modificadas y metodo para producir las mismas. |
WO2005062923A2 (en) * | 2003-12-24 | 2005-07-14 | Massachusetts Institute Of Technology | Gene targets for enhanced carotenoid production |
US7741070B2 (en) | 2003-12-24 | 2010-06-22 | Massachusetts Institute Of Technology | Gene targets for enhanced carotenoid production |
US7608699B2 (en) * | 2003-12-29 | 2009-10-27 | Rockefeller University | Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof |
JP2007520222A (ja) | 2004-01-20 | 2007-07-26 | アイシス ファーマシューティカルズ インコーポレイテッド | グルココルチコイドレセプター発現の調節 |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
CA2799245C (en) | 2004-02-25 | 2016-08-30 | Pioneer Hi-Bred International, Inc. | Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof |
EP3543324B1 (de) | 2004-02-27 | 2022-11-30 | BASF Plant Science GmbH | Verfahren zur herstellung mehrfach ungesättigten fettsäuren in transgenen pflanzen |
CA2558726C (en) | 2004-02-27 | 2017-11-07 | Basf Plant Science Gmbh | Method for producing unsaturated .omega.-3-fatty acids in transgenic organisms |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US8790919B2 (en) * | 2004-03-15 | 2014-07-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNase H |
US8314226B2 (en) * | 2004-03-29 | 2012-11-20 | The General Hospital Corporation | Oligonucleotide complex compositions and methods of use as gene alteration tools |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
EP2540734B1 (en) | 2004-04-05 | 2016-03-30 | Alnylam Pharmaceuticals, Inc. | Process and reagents for oligonucleotide synthesis and purification |
US7420099B2 (en) * | 2004-04-22 | 2008-09-02 | Kirin Holdings Kabushiki Kaisha | Transgenic animals and uses thereof |
US20070072815A1 (en) * | 2004-05-04 | 2007-03-29 | Kmiec Eric B | Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration |
US7825293B2 (en) | 2004-05-28 | 2010-11-02 | Cropdesign N.V. | Plants having improved growth characteristics and a method for making the same |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
CA2735315A1 (en) | 2004-06-09 | 2005-12-29 | Pioneer Hi-Bred International, Inc. | Plastid transit peptides |
WO2007087815A2 (en) | 2004-12-17 | 2007-08-09 | Metanomics Gmbh | Process for the control of production of fine chemicals |
WO2006069610A2 (en) | 2004-07-02 | 2006-07-06 | Metanomics Gmbh | Process for the production of fine chemicals |
US8680062B2 (en) | 2004-07-06 | 2014-03-25 | Deliversir Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
US7928288B2 (en) | 2004-07-12 | 2011-04-19 | Cropdesign N.V. | Plants having improved growth characteristics and method for making the same |
ES2430827T3 (es) | 2004-07-31 | 2013-11-21 | Metanomics Gmbh | Preparación de organismos con crecimiento más rápido y/o rendimiento más alto |
PT2409713E (pt) | 2004-08-10 | 2015-10-09 | Genzyme Corp | Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos |
EP1778845A2 (en) | 2004-08-16 | 2007-05-02 | CropDesign N.V. | Plants having improved growth characteristics and method for making the same |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
EP1799812A4 (en) | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS |
AU2005286738A1 (en) | 2004-09-17 | 2006-03-30 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
AU2005286428B2 (en) | 2004-09-24 | 2012-08-23 | Basf Plant Science Gmbh | Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
US8765700B2 (en) | 2004-10-20 | 2014-07-01 | Antisense Therapeutics Ltd. | Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions |
US20080108502A1 (en) | 2004-10-29 | 2008-05-08 | Cropdesign N.V. | Plants Having Improved Growth Characteristics And Method For Making The Same |
AR051866A1 (es) | 2004-12-24 | 2007-02-14 | Cropdesign Nv | Plantas con aumento del rendimiento y metodo de prepracion |
WO2006071219A1 (en) | 2004-12-28 | 2006-07-06 | Pioneer Hi-Bred International, Inc. | Improved grain quality through altered expression of seed proteins |
CN101111600A (zh) | 2005-01-27 | 2008-01-23 | 克罗普迪塞恩股份有限公司 | 产率增加的植物及其制备方法 |
EP1851317B1 (en) | 2005-02-23 | 2011-10-26 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome p450 genes |
EP1871883A1 (en) | 2005-03-02 | 2008-01-02 | Metanomics GmbH | Process for the production of fine chemicals |
US20140199313A1 (en) | 2005-03-02 | 2014-07-17 | Metanomics Gmbh | Process for the Production of Fine Chemicals |
WO2006094976A2 (en) | 2005-03-08 | 2006-09-14 | Basf Plant Science Gmbh | Expression enhancing intron sequences |
MX2007010922A (es) | 2005-03-10 | 2007-10-12 | Genentech Inc | Metodos y composiciones para modular la integridad vascular. |
DE102005013779A1 (de) | 2005-03-22 | 2006-09-28 | Basf Plant Science Gmbh | Verfahren zur Herstellung von mehrfach ungesättigten C20- und C22-Fettsäuren mit mindestens vier Doppelbindungen in transgenen Pflanzen |
EP1707632A1 (de) | 2005-04-01 | 2006-10-04 | Bayer CropScience GmbH | Phosphorylierte waxy-Kartoffelstärke |
EP1874936B1 (en) | 2005-04-19 | 2013-10-30 | BASF Plant Science GmbH | Improved methods controlling gene expression |
WO2006113666A2 (en) | 2005-04-19 | 2006-10-26 | Massachusetts Institute Of Technology | Amphiphilic polymers and methods of use thereof |
US20070011752A1 (en) * | 2005-05-06 | 2007-01-11 | American Integrated Biologics, Inc. | Production of human proteins in transgenic animal saliva |
EP2261362A3 (en) | 2005-05-25 | 2011-04-20 | Pioneer Hi-Bred International Inc. | Methods for improving crop plant architecture and yield |
WO2007008300A2 (en) | 2005-05-31 | 2007-01-18 | ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
BRPI0612671A2 (pt) | 2005-06-23 | 2010-11-30 | Basf Plant Science Gmbh | métodos melhorados para a produção de plantas férteis zea mays (milho) estavelmente transformadas |
US8119858B2 (en) | 2005-07-06 | 2012-02-21 | Cropdesign N.V. | Plant yield improvement by Ste20-like gene expression |
DE102005038036A1 (de) | 2005-08-09 | 2007-02-15 | Basf Plant Science Gmbh | Verfahren zur Herstellung von Arachidonsäure und/oder Eicosapentaensäure in transgenen Nutzpflanzen |
EP1915452A2 (en) | 2005-08-12 | 2008-04-30 | BASF Plant Science GmbH | Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
US7842856B2 (en) | 2005-08-25 | 2010-11-30 | The Board Of Trustees Of The University Of Illinois | Herbicide resistance gene, compositions and methods |
EP1931788A2 (en) | 2005-09-15 | 2008-06-18 | CropDesign N.V. | Plants having increased yield and method for making the same |
EP1931789B1 (en) | 2005-09-20 | 2016-05-04 | BASF Plant Science GmbH | Methods for controlling gene expression using ta-siran |
GB2431158A (en) | 2005-10-13 | 2007-04-18 | Rothamsted Res Ltd | Process for the production of arachidonic and/or eicosapentaenoic acid |
US8853492B2 (en) | 2005-11-07 | 2014-10-07 | Cropdesign N.V. | Plants having improved growth characteristics and a method for making the same |
WO2007051866A2 (en) | 2005-11-07 | 2007-05-10 | Cropdesign N.V. | Plants having improved growth characteristics and a method for making the same |
CA2628505A1 (en) | 2005-11-08 | 2007-05-18 | Basf Plant Science Gmbh | Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants |
AU2006311005B2 (en) | 2005-11-08 | 2013-06-06 | Cropdesign N.V. | Plants having improved growth characteristics and a method for making the same |
AU2006315788A1 (en) | 2005-11-10 | 2007-05-24 | Pioneer Hi-Bred International, Inc. | Dof (DNA binding with one finger) sequences and methods of use |
US20070199096A1 (en) | 2005-11-14 | 2007-08-23 | E.I. Du Pont De Nemours And Company | Compositions and Methods for Altering Alpha- and Beta-Tocotrienol Content |
CA2630602A1 (en) | 2005-11-21 | 2007-05-31 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
US7723574B2 (en) | 2005-11-24 | 2010-05-25 | Basf Plant Science Gmbh | Process for the production of Δ5-unsaturated fatty acids in transgenic organisms |
EP1957034A2 (de) * | 2005-11-24 | 2008-08-20 | Basf Se | Chimäre keratinbindende effektorproteine |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
EP2157172A3 (en) | 2005-12-01 | 2010-03-24 | CropDesign N.V. | Plants having improved growth characteristics and methods for making the same |
US20090105341A1 (en) | 2005-12-24 | 2009-04-23 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
US7592505B2 (en) | 2005-12-30 | 2009-09-22 | Pioneer Hi-Bred International, Inc. | UDP-xylose synthases (UXS) polynucleotides, polypeptides, and uses thereof |
EP1979484B1 (en) | 2006-01-12 | 2014-03-19 | BASF Plant Science GmbH | Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants |
EP2465341B1 (en) | 2006-01-12 | 2014-12-17 | Cibus Europe B.V. | EPSPS Mutants |
JP5425474B2 (ja) | 2006-01-26 | 2014-02-26 | アイシス ファーマシューティカルズ, インコーポレーテッド | ハンチンチン対する、組成物及びその使用 |
PL1984381T3 (pl) | 2006-01-27 | 2011-03-31 | Isis Pharmaceuticals Inc | Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych |
US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
CA2895745A1 (en) | 2006-02-09 | 2007-08-16 | Pioneer Hi-Bred International, Inc. | Genes for enhancing nitrogen utilization efficiency in crop plants |
GB0603160D0 (en) | 2006-02-16 | 2006-03-29 | Rothamsted Res Ltd | Nucleic acid |
EP2343376A3 (en) | 2006-03-24 | 2011-11-23 | BASF Plant Science GmbH | Proteins associated with abiotic stress response and homologs |
CA2638978A1 (en) | 2006-03-31 | 2007-10-11 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
AU2007299219A1 (en) | 2006-04-05 | 2008-03-27 | Metanomics Gmbh | Process for the production of a fine chemical |
EP2251349A1 (en) | 2006-04-19 | 2010-11-17 | Pioneer Hi-Bred International, Inc. | Isolated polynucleotide molecules corresponding to mutant and wild-type alleles of the maize D9 gene and methods of use |
EP2019692B1 (en) | 2006-05-05 | 2014-06-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of gccr |
JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ, インコーポレーテッド | 5’修飾二環式核酸類似体 |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
EP2441839A1 (en) | 2006-05-30 | 2012-04-18 | CropDesign N.V. | Plants with reduced expression of REVOLUTA (REV) having enhanced yield-related traits and a method for making the same |
CA2651961A1 (en) | 2006-05-31 | 2007-12-06 | Metanomics Gmbh | Manipulation of the nitrogen metabolism |
CA2649341A1 (en) | 2006-06-08 | 2007-12-13 | Basf Plant Science Gmbh | Plants having improved growth characteristics and method for making the same |
EP2599869A3 (en) | 2006-06-15 | 2013-09-11 | CropDesign N.V. | Plants having enhanced yield-related traits and a method for making the same |
CN105087634A (zh) | 2006-06-15 | 2015-11-25 | 克罗普迪塞恩股份有限公司 | 具有增强的产量相关性状的nac转录因子受调节表达的植物和用于产生该植物的方法 |
RU2483057C2 (ru) | 2006-06-28 | 2013-05-27 | Ньюселис Инк. | Смеси жирных кислот и их применение |
US8198253B2 (en) | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
MX2009001177A (es) | 2006-08-02 | 2009-02-13 | Cropdesign Nv | Plantas con caracteristicas mejoradas y un metodo para producirlas. |
ES2558133T3 (es) | 2006-08-02 | 2016-02-02 | Cropdesign N.V. | Plantas transformadas con el polipéptido SYT que tienen el rendimiento aumentado en estrés abiótico y procedimiento de producción de las mismas |
AU2007291330B2 (en) | 2006-08-30 | 2013-01-17 | Basf Plant Science Gmbh | Method for increasing resistance to pathogens in transgenic plants |
US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
AU2007294858B2 (en) | 2006-09-14 | 2011-05-12 | Medgenics Medical Israel, Ltd | Long lasting drug formulations |
EP2177605B1 (de) | 2006-10-06 | 2014-12-10 | BASF Plant Science GmbH | Delta-5 Desaturasen und Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenen nicht-humanen Organismen |
US8329988B2 (en) | 2006-10-12 | 2012-12-11 | Basf Plant Science Gmbh | Method for increasing pathogen resistance in transgenic plants |
CN101589148B (zh) | 2006-10-13 | 2014-07-02 | 巴斯福植物科学有限公司 | 产量提高的植物 |
BRPI0720192A2 (pt) | 2006-10-24 | 2013-12-31 | Basf Plant Science Gmbh | Método para gerar ou aumentar uma resistência a pelo menos um fungo biotrófico em uma planta ou uma parte de uma planta, seqüência de polipeptídio artificial, seqüência de ácido nucléico artificial, cassete de expressão recombinante, vetor recombinante, e, microorganismo recombinante |
WO2008059048A1 (en) | 2006-11-16 | 2008-05-22 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same using consensus sequences from the yabby protein family |
BRPI0718977A2 (pt) | 2006-11-24 | 2014-02-04 | Cropdesign Nv | Método para aumentar rendimento de sementes em plantas em relação às plantas de controle, construção, uso da mesma, planta, parte de planta ou célula de planta, método para a produção de uma planta transgênica tendo redimento aumentado de sementes em relação às plantas de controle, planta transgênica, partes colhíveis de uma planta, produtos, e, uso de um ácido nucleico |
WO2008071767A1 (en) | 2006-12-15 | 2008-06-19 | Cropdesign N.V. | Plants having enhanced seed yield-related traits and a method for making the same |
EP2395093A3 (en) | 2006-12-21 | 2012-08-01 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
EP1935428A1 (en) * | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
EP2102364B1 (en) | 2006-12-28 | 2019-01-23 | Pioneer Hi-Bred International, Inc. | Genetic markers for orobanche resistance in sunflower |
AU2007342674B2 (en) * | 2007-01-10 | 2013-09-19 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
WO2008087141A2 (en) | 2007-01-15 | 2008-07-24 | Basf Plant Science Gmbh | Use of subtilisin (rnr9) polynucleotides for achieving a pathogen resistance in plants |
CN101627125B (zh) | 2007-01-30 | 2013-05-15 | 克罗普迪塞恩股份有限公司 | 具有增强的产量相关性状的植物及其制备方法 |
CN103233037A (zh) | 2007-01-31 | 2013-08-07 | 巴斯福植物科学有限公司 | 具有增强的产量相关性状和/或提高的非生物胁迫抗性的植物和制备该植物的方法 |
KR101488800B1 (ko) | 2007-02-09 | 2015-02-04 | 노오쓰웨스턴 유니버시티 | 세포내 타겟 검출용 입자 |
MX2009008600A (es) | 2007-02-28 | 2009-08-21 | Cropdesign Nv | Plantas con rasgos mejorados relacionados con el rendimiento y un metodo para producirlas. |
US8153863B2 (en) * | 2007-03-23 | 2012-04-10 | New York University | Transgenic plants expressing GLK1 and CCA1 having increased nitrogen assimilation capacity |
NZ600923A (en) | 2007-04-04 | 2013-10-25 | Basf Plant Science Gmbh | AHAS mutants |
US9156865B2 (en) | 2007-04-23 | 2015-10-13 | Deliversir Ltd | System for delivering therapeutic agents into living cells and cells nuclei |
US9556210B2 (en) | 2007-04-23 | 2017-01-31 | Sabag-Rfa Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
EP2144633B1 (en) * | 2007-04-23 | 2014-07-16 | Deliversir Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
EP2069509B1 (en) | 2007-05-03 | 2013-09-18 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
AU2008252996B2 (en) | 2007-05-22 | 2014-01-30 | Basf Plant Science Gmbh | Plants with increased tolerance and/or resistance to environmental stress and increased biomass production |
CA2687635A1 (en) | 2007-05-22 | 2008-11-27 | Basf Plant Science Gmbh | Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production-ko |
EP2172556B1 (en) | 2007-05-23 | 2015-07-22 | CropDesign N.V. | Plants having enhanced yield-related traits and a method for making the same |
EP2152733A2 (en) | 2007-05-25 | 2010-02-17 | CropDesign N.V. | Yield enhancement in plants by modulation of maize alfins |
DK2160464T3 (da) | 2007-05-30 | 2014-08-04 | Univ Northwestern | Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser |
WO2008150729A2 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
EP2508610A1 (en) | 2007-06-29 | 2012-10-10 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
EP2176280B2 (en) | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
CN104404078A (zh) | 2007-07-20 | 2015-03-11 | 巴斯夫植物科学有限公司 | 具有增强的产率相关性状的植物及其制备方法 |
AR067748A1 (es) | 2007-07-31 | 2009-10-21 | Basf Plant Science Gmbh | Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas |
EP2183372A2 (en) | 2007-07-31 | 2010-05-12 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
WO2009023855A2 (en) | 2007-08-15 | 2009-02-19 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
US9617557B2 (en) | 2007-09-14 | 2017-04-11 | Basf Plant Science Gmbh | Plants having increased yield-related traits by expressing a growth-regulating factor (GRF) polypeptide and method for making the same |
CN103695459A (zh) | 2007-09-18 | 2014-04-02 | 巴斯夫植物科学有限公司 | 产量提高的植物 |
JP2010538670A (ja) | 2007-09-21 | 2010-12-16 | ビーエーエスエフ プラント サイエンス ゲーエムベーハー | 増強された収穫高関連形質を有する植物およびその作製方法 |
CN101939435A (zh) | 2007-09-21 | 2011-01-05 | 巴斯夫植物科学有限公司 | 具有增加的产量的植物 |
WO2009039442A1 (en) | 2007-09-21 | 2009-03-26 | California Institute Of Technology | Nfia in glial fate determination, glioma therapy and astrocytoma treatment |
BR122018070230B1 (pt) | 2007-10-05 | 2023-01-10 | Cibus Europe B.V. | Método para produção de planta resistente à herbicida |
US20100280098A1 (en) * | 2007-10-05 | 2010-11-04 | Juliano Rudolph L | Receptor targeted oligonucleotides |
US20090111099A1 (en) * | 2007-10-27 | 2009-04-30 | Yongsheng Ma | Promoter Detection and Analysis |
US20110071047A1 (en) * | 2007-10-27 | 2011-03-24 | O.D. 260 Inc. | Promoter detection and analysis |
WO2009056566A2 (en) | 2007-10-29 | 2009-05-07 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
WO2009064771A2 (en) | 2007-11-12 | 2009-05-22 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome p450 genes |
EP2219680A2 (en) | 2007-11-13 | 2010-08-25 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
MX2010005565A (es) | 2007-11-20 | 2010-06-11 | Pioneer Hi Bred Int | Genes de señalizacion de etileno en maiz y su modulacion para mejor tolerancia al estres en plantas. |
USRE47320E1 (en) | 2007-11-20 | 2019-03-26 | Ionis Pharmaceuticals, Inc. | Modulation of CD40 expression |
US8546556B2 (en) * | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
US8704043B2 (en) | 2007-11-22 | 2014-04-22 | Cropdesign N.V. | Plants having increased yield-related traits and a method for making the same |
EP2220111A1 (en) | 2007-11-26 | 2010-08-25 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
BRPI0821748A2 (pt) * | 2007-12-19 | 2019-09-24 | Basf Plant Science Gmbh | método para produzir uma planta com rendimento aumentado, molécula isolada de ácido nucleico, construção de ácido nucleico, vetor, processo para produzir um polipeptídeo, polipeptídeo, anticorpo, núcleo de célula de planta, célula de planta, tecido de planta, material de propagação, semente, pólen, progênie, ou uma parte de planta, ou uma planta com rendimento aumento, processo para a indentificação de um composto, método para a produção de uma composição agrícola, composição, polipeptídeo ou molécula de ácido nucleico, uso dos ácidos nucléicos, e, método para a indentificação de uma planta com um rendimento aumentado |
CA2708506A1 (en) | 2007-12-20 | 2009-07-02 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
AU2008340002A1 (en) | 2007-12-21 | 2009-07-02 | Basf Plant Science Gmbh | Plants with increased yield (KO NUE) |
ES2653573T3 (es) * | 2007-12-27 | 2018-02-07 | Cibus Europe B.V. | Mezclas de éster butílico de ácido graso |
EP2599875A3 (en) | 2008-01-25 | 2013-07-17 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
EP2247733A2 (en) | 2008-01-31 | 2010-11-10 | National Institute of Biological Sciences | Plants having altered growth and/or development and a method for making the same |
WO2009100320A2 (en) | 2008-02-07 | 2009-08-13 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
CA2716180A1 (en) | 2008-02-27 | 2009-09-03 | Basf Plant Science Gmbh | Plants with increased yield |
EP2282744B1 (en) | 2008-03-21 | 2018-01-17 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucleosides and methods for their use |
DK2285819T3 (da) | 2008-04-04 | 2013-12-02 | Isis Pharmaceuticals Inc | Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider |
EP3029143A1 (en) | 2008-04-16 | 2016-06-08 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
AU2009243552A1 (en) | 2008-05-05 | 2009-11-12 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
KR20110023862A (ko) * | 2008-05-23 | 2011-03-08 | 시부스 오일즈, 엘엘씨 | 효모를 사용한 스쿠알렌 생산 |
CA2724993A1 (en) | 2008-06-20 | 2009-12-23 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EP2975130A3 (en) | 2008-06-26 | 2016-04-20 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
CN102143971A (zh) | 2008-07-04 | 2011-08-03 | 巴斯夫植物科学有限公司 | 通过过表达编码tfl-1 样蛋白的多核苷酸而具有增强的产量相关性状的植物及其制备方法 |
WO2010007035A1 (en) | 2008-07-17 | 2010-01-21 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
MX2011000778A (es) | 2008-07-31 | 2011-03-15 | Basf Plant Science Gmbh | Plantas con caracteristicas modificadas de crecimiento y un metodo para obtenerlas. |
EP2324044A4 (en) | 2008-08-04 | 2012-04-25 | Univ Miami | STING (INTERFERON GENE STIMULATOR), A REGULATOR OF INDIAN IMMUNE RESPONSES |
WO2010020654A2 (en) | 2008-08-19 | 2010-02-25 | Basf Plant Science Gmbh | Plants with increased yield by increasing or generating one or more activities in a plant or a part thereof |
MX2011001475A (es) | 2008-08-20 | 2011-03-29 | Basf Plant Science Gmbh | Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas. |
MX2011002143A (es) | 2008-08-25 | 2011-07-20 | Excaliard Pharmaceuticals Inc | Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos. |
CA2737303C (en) | 2008-09-11 | 2019-06-11 | Keygene N.V. | Method for diagnostic marker development |
US20110195843A1 (en) | 2008-09-23 | 2011-08-11 | Basf Plant Science Gmbh | Plants with Increased Yield (LT) |
WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
US8604192B2 (en) | 2008-09-24 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acids analogs |
MX2011002675A (es) | 2008-09-24 | 2011-04-21 | Basf Plant Science Gmbh | Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas. |
AP2011005671A0 (en) | 2008-09-26 | 2011-04-30 | Basf Agrochemical Products Bv | Herbicide-resistant AHAS-mutants and methods of use. |
BRPI0920263B1 (pt) | 2008-10-15 | 2021-09-21 | Ionis Pharmaceuticals, Inc | Compostos compreendendo um oligonucleotídeo modificado, composição e uso dos mesmos |
AU2009322865B2 (en) * | 2008-10-20 | 2013-07-18 | Moerae Matrix, Inc. | Polypeptide for treating or preventing adhesions |
AR075465A1 (es) | 2008-10-22 | 2011-04-06 | Basf Se | Uso de herbicidas de sulfonilurea en plantas cultivadas |
WO2010046422A2 (en) | 2008-10-22 | 2010-04-29 | Basf Se | Use of auxin type herbicides on cultivated plants |
AR073969A1 (es) | 2008-10-23 | 2010-12-15 | Basf Plant Science Gmbh | Un metodo para producir una celula transgenca con mayor contenido de acido gamma aminobutirico ( gaba) |
CN102264907A (zh) | 2008-10-23 | 2011-11-30 | 巴斯夫植物科学有限公司 | 产量增加的植物(nue) |
WO2010048549A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
EP2358398A2 (en) | 2008-10-24 | 2011-08-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
WO2010056519A1 (en) | 2008-10-30 | 2010-05-20 | Pioneer Hi-Bred International, Inc. | Manipulation of glutamine synthetases (gs) to improve nitrogen use efficiency and grain yield in higher plants |
EP2184351A1 (en) | 2008-10-30 | 2010-05-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Polynucleotides encoding caryophyllene synthase and uses thereof |
CA2741973A1 (en) | 2008-11-12 | 2010-05-20 | Basf Plant Science Gmbh | Plants having enhanced abiotic stress tolerance and/or enhanced yield-related traits and a method for making the same |
KR101336213B1 (ko) | 2008-11-14 | 2013-12-05 | 후지안 후다 바이오테크 코퍼레이션 리미티드 | 열내성 비 k12 에스체리치아 콜리 피타아제 및 그 제조 |
US9139827B2 (en) | 2008-11-24 | 2015-09-22 | Northwestern University | Polyvalent RNA-nanoparticle compositions |
EA201170752A1 (ru) | 2008-12-03 | 2012-04-30 | Басф Плант Сайенс Гмбх | Растения с повышенной устойчивостью к абиотическому стрессу и/или улучшенными характеристиками урожайности и способ их получения |
CN108042560A (zh) | 2008-12-04 | 2018-05-18 | 库尔纳公司 | 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病 |
US8431775B2 (en) | 2008-12-04 | 2013-04-30 | Pioneer Hi Bred International Inc | Methods and compositions for enhanced yield by targeted expression of knotted1 |
JP6091752B2 (ja) | 2008-12-04 | 2017-03-08 | クルナ・インコーポレーテッド | Epoに対する天然アンチセンス転写物の抑制によるエリスロポエチン(epo)関連疾患の治療 |
CN107338251A (zh) | 2008-12-04 | 2017-11-10 | 库尔纳公司 | 通过抑制肿瘤抑制基因的天然反义转录物***抑制基因相关性疾病 |
US9327008B2 (en) | 2008-12-10 | 2016-05-03 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
PL2376638T3 (pl) | 2008-12-12 | 2014-01-31 | Basf Plant Science Gmbh | Desaturazy oraz sposób wytwarzania wielonienasyconych kwasów tłuszczowych w organizmach transgenicznych |
AU2009335740B2 (en) | 2008-12-17 | 2016-04-21 | Sarepta Therapeutics, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
DE112009003749T5 (de) | 2008-12-17 | 2012-11-15 | Basf Plant Science Gmbh | Pflanzen mit gesteigerten ertragsbezogenen Eigenschaften und/oder gesteigerter abiotischerStresstoleranz und Verfahren zur Herstellung derselben |
EP2204086A1 (en) | 2009-01-02 | 2010-07-07 | Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK) | Six row-type barley |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
US8653080B2 (en) | 2009-01-14 | 2014-02-18 | Salk Institute For Biological Studies | Methods for screening and compounds that protect against amyloid diseases |
US20110283420A1 (en) | 2009-01-28 | 2011-11-17 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
WO2010091308A2 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
WO2010090969A1 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
HUE026280T2 (en) | 2009-02-12 | 2016-06-28 | Curna Inc | Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t |
EP2396408B1 (en) | 2009-02-12 | 2017-09-20 | CuRNA, Inc. | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
DE112010000887T5 (de) | 2009-02-25 | 2012-09-27 | Basf Plant Science Company Gmbh | Pflanzen mit gesteigerten Ertragsmerkmalen und Verfahren zu deren Herstellung |
US8716553B2 (en) | 2009-03-02 | 2014-05-06 | Pioneer Hi Bred International Inc | NAC transcriptional activators involved in abiotic stress tolerance |
EP2963116B1 (en) | 2009-03-04 | 2020-11-11 | CuRNA, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 |
JP6116242B2 (ja) | 2009-03-16 | 2017-04-19 | クルナ・インコーポレーテッド | 核因子(赤血球由来2)様2(nrf2)に対する天然アンチセンス転写物の抑制によるnrf2関連疾患の治療 |
JP5904935B2 (ja) | 2009-03-17 | 2016-04-20 | クルナ・インコーポレーテッド | デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療 |
UA108071C2 (uk) | 2009-04-14 | 2015-03-25 | Піонер Хай-Бред Інтернешнл, Інк. | Спосіб поліпшення витривалості до нестачі азоту у рослини |
CA2759100A1 (en) | 2009-04-21 | 2010-10-28 | Basf Plant Science Company Gmbh | Rna-mediated induction of gene expression in plants |
US20120047602A1 (en) | 2009-04-21 | 2012-02-23 | Basf Plant Science Company Gmbh | RNA-Mediated Induction of Gene Expression in Plants |
EP3248618A1 (en) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
KR20150046788A (ko) | 2009-04-29 | 2015-04-30 | 바스프 플랜트 사이언스 게엠베하 | 향상된 수확량 관련 형질을 갖는 식물 및 이의 제조 방법 |
CA2760266A1 (en) | 2009-04-29 | 2010-11-04 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
DK2424987T3 (en) | 2009-05-01 | 2018-02-26 | Curna Inc | TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG |
MX2011011678A (es) | 2009-05-04 | 2011-12-06 | Pioneer Hi Bred Int | Mejora de la produccion en plantas mediante la modulacion del factor de transcripcion ap2. |
CN103223177B (zh) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
US20120096593A1 (en) | 2009-05-06 | 2012-04-19 | Yves Hatzfeld | Plants Having Enhanced Yield-Related Traits And/Or Enhanced Abiotic Stress Tolerance And A Method For Making The Same |
WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
KR101703695B1 (ko) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | 전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료 |
KR20120024819A (ko) | 2009-05-28 | 2012-03-14 | 오피케이오 큐알엔에이, 엘엘씨 | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료 |
KR101702689B1 (ko) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료 |
ES2620960T3 (es) | 2009-06-16 | 2017-06-30 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen de colágeno mediante la inhibición de un transcrito antisentido natural a un gen de colágeno |
US9683023B2 (en) | 2009-06-19 | 2017-06-20 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
KR101807324B1 (ko) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료 |
BRPI1008189A2 (pt) | 2009-06-30 | 2015-08-25 | Du Pont | Planta transgenica semente transgenica obtida a partir da planta transgencia semente transgencia metodo de produção de uma planta transgenica metodo de produção de sementes transgenicas metodo de produto e ou subproduto da semente transgenica e semente transgenica obtida pelo metodo |
ES2385451T3 (es) | 2009-07-10 | 2012-07-25 | Freie Universität Berlin | Rock2 y Rock3, dos nuevas variantes de ganancia de función de los receptores de citoquinina AHK2 y AHK3 |
EP2275564A1 (en) | 2009-07-17 | 2011-01-19 | Freie Universität Berlin | Means and method for the production of transgenic plants that are resistant to clubroot |
MX2012000928A (es) | 2009-07-23 | 2012-03-29 | Basf Plant Science Co Gmbh | Plantas con produccion aumentada. |
CA2768571A1 (en) | 2009-07-24 | 2011-01-27 | Pioneer Hi-Bred International, Inc. | The use of dimerization domain component stacks to modulate plant architecture |
US9890195B2 (en) * | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
WO2011017492A2 (en) | 2009-08-05 | 2011-02-10 | Pioneer Hi-Bred International, Inc. | Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants |
ES2585360T3 (es) | 2009-08-05 | 2016-10-05 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS) |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
GB0914012D0 (en) | 2009-08-11 | 2009-09-16 | Plant Bioscience Ltd | Stress tolerant plants |
BR112012003796A2 (pt) | 2009-08-19 | 2016-11-22 | Basf Plant Science Co Gmbh | método para intensificar traços relacionados ao rendimento em plantas com relação às plantas de controle, construto, uso de um construto, planta, parte de planta ou célula de planta, método para a produção de uma planta trangênica, partes colhíveis de uma planta, produtos, e, uso de um ácido nucleico. |
CN102549149A (zh) | 2009-08-20 | 2012-07-04 | 先锋国际良种公司 | 在玉蜀黍中功能性表达酵母硝酸盐转运蛋白(ynt1)以改善硝酸盐吸收 |
WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
SG178388A1 (en) | 2009-08-31 | 2012-03-29 | Basf Plant Science Co Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific and/or seed-preferential gene expression in plants |
CA2772267A1 (en) | 2009-08-31 | 2011-03-03 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing seed-specific gene expression in plants promoting enhanced polyunsaturated fatty acid synthesis |
CA3235747A1 (en) | 2009-08-31 | 2011-03-03 | Basf Plant Science Company Gmbh | Regulatory nucleic acid molecules for enhancing constitutive gene expression in plants |
CA2772715C (en) | 2009-09-02 | 2019-03-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EP3118320A1 (en) | 2009-09-25 | 2017-01-18 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
BR112012006616A2 (pt) | 2009-09-25 | 2018-07-10 | Basf Plant Science Co Gmbh | método para intensificar traços relacionados a rendimento em plantas com relação a plantas de controle, planta ou parte da mesma, construto, uso de um construto, planta. ou parte da planta ou célula de planta transformada com um construto, método para a produção de uma planta transgênica, planta transgênica, partes colhíveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco, molécula de ácido nucleíco isolado, polipeptídeo isolado, uso de qualquer um, dois ou mais ácidos nucleícos e método para aprimorar os traços relacionados a rendimento em plantas. |
WO2011041796A1 (en) | 2009-10-02 | 2011-04-07 | Pioneer Hi-Bred International, Inc. | Down-regulation of acc synthase for improved plant performance |
WO2011050194A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
CN102666858A (zh) | 2009-10-22 | 2012-09-12 | 巴斯夫植物科学有限公司 | 具有增强的产量相关性状的植物和用于产生该植物的方法 |
US9376690B2 (en) | 2009-10-30 | 2016-06-28 | Northwestern University | Templated nanoconjugates |
AR078829A1 (es) | 2009-10-30 | 2011-12-07 | Du Pont | Plantas y semillas con niveles alterados de compuesto de almacenamiento, construcciones relacionadas y metodos relacionados con genes que codifican proteinas similares a las aldolasas bacterianas de la clase ii del acido 2,4- dihidroxi-hept-2-eno-1,7-dioico |
EP3199634A1 (en) | 2009-11-13 | 2017-08-02 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
DE112010004383T5 (de) | 2009-11-13 | 2012-08-23 | Basf Plant Science Company Gmbh | Pflanzen mit gesteigerten Ertragsmerkmalen und Verfahren zu deren Herstellung |
WO2011061656A1 (en) | 2009-11-17 | 2011-05-26 | Basf Plant Science Company Gmbh | Plants with increased yield |
DK3219815T3 (da) | 2009-11-23 | 2019-12-16 | Cibus Europe Bv | Fremgangsmåder og sammensætninger til at fremstille squalen under anvendelse af gær |
JP5856065B2 (ja) | 2009-11-30 | 2016-02-09 | ジェネンテック, インコーポレイテッド | 腫瘍の診断と治療のための組成物と方法 |
JP6025567B2 (ja) | 2009-12-16 | 2016-11-16 | カッパーアールエヌエー,インコーポレイテッド | 膜結合転写因子ペプチダーゼ、部位1(mbtps1)に対する天然アンチセンス転写物の阻害によるmbtps1関連性疾患の治療 |
WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
RU2619185C2 (ru) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2 |
US8946514B2 (en) | 2009-12-28 | 2015-02-03 | E.I. Du Pont De Nemours And Company | Sorghum fertility restorer genotypes and methods of marker-assisted selection |
JP5982288B2 (ja) | 2009-12-29 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | 腫瘍タンパク質63(p63)に対する天然アンチセンス転写物の阻害による腫瘍タンパク質63関連疾患の治療 |
CA2785173A1 (en) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
WO2011082304A1 (en) | 2009-12-31 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
NO2521784T3 (zh) | 2010-01-04 | 2018-05-05 | ||
CA2786741A1 (en) | 2010-01-06 | 2011-07-14 | Pioneer Hi-Bred International, Inc. | Identification of diurnal rhythms in photosynthetic and non-photosynthetic tissues from zea mays and use in improving crop plants |
RU2612161C2 (ru) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы |
WO2011085102A1 (en) | 2010-01-11 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
ES2664866T3 (es) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg |
US20110236325A1 (en) | 2010-01-21 | 2011-09-29 | NellOne Therapeutics, Inc. | Methods to treat or prevent a skin condition using a nell1 peptide |
CN102782135A (zh) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病 |
US9970021B2 (en) | 2010-01-26 | 2018-05-15 | Pioneer Hi-Bred International, Inc. | HPPD-inhibitor herbicide tolerance |
KR101838308B1 (ko) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | 피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료 |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
JP5988436B2 (ja) | 2010-02-23 | 2016-09-07 | ジェネンテック, インコーポレイテッド | 腫瘍の診断と治療のための組成物と方法 |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2011104128A2 (en) | 2010-02-24 | 2011-09-01 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
WO2011104155A2 (en) | 2010-02-24 | 2011-09-01 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EP2361985A1 (en) | 2010-02-26 | 2011-08-31 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
EP2361927A1 (en) | 2010-02-26 | 2011-08-31 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
CA2790836A1 (en) | 2010-03-03 | 2011-09-09 | E.I. Du Pont De Nemours And Company | Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding oxidoreductase motif polypeptides |
GB201003702D0 (en) | 2010-03-05 | 2010-04-21 | Univ Warwick | Molecular engineering of a floral inducer for crop improvement |
WO2011112732A2 (en) | 2010-03-12 | 2011-09-15 | The Brigham And Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
EP2545173A2 (en) | 2010-03-12 | 2013-01-16 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
WO2011115818A1 (en) | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
BR112012023505A2 (pt) | 2010-03-18 | 2015-09-01 | Basf Plant Science Co Gmbh | Método para intensificar traços relacionados a rendimento em plantas em relação a plantas de controle, planta ou parte da mesma, uso de um construto, método para a produção de uma planta transgênica dotada de rendimento aumentado, planta transgênica, partes colhíveis de uma planta, produtos derivados de uma planta e uso de um ácido nucleico |
EP2547195A4 (en) | 2010-03-18 | 2014-01-08 | Basf Plant Science Co Gmbh | PLANTS WITH IMPROVED PERFORMANCE CHARACTERISTICS AND METHOD FOR THE PRODUCTION THEREOF |
CA2793394A1 (en) | 2010-03-19 | 2011-09-22 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
CA2793388A1 (en) | 2010-03-19 | 2011-09-22 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EP2371845A1 (en) | 2010-03-22 | 2011-10-05 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
EP3517613A1 (en) | 2010-04-09 | 2019-07-31 | CuRNA, Inc. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
EP2385129A1 (en) | 2010-05-03 | 2011-11-09 | BASF Plant Science Company GmbH | Enhanced methods for gene regulation in plants |
AU2011248625B2 (en) | 2010-04-26 | 2017-01-05 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
JP6005628B2 (ja) | 2010-04-28 | 2016-10-12 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物 |
US9127033B2 (en) | 2010-04-28 | 2015-09-08 | Isis Pharmaceuticals, Inc. | 5′ modified nucleosides and oligomeric compounds prepared therefrom |
WO2011139853A2 (en) | 2010-04-28 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
US9068177B2 (en) | 2010-04-29 | 2015-06-30 | Atyr Pharma, Inc | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
JP6008838B2 (ja) | 2010-04-29 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | アスパラギニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
CA2994063A1 (en) | 2010-04-29 | 2011-11-10 | Ionis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
CN103118693B (zh) | 2010-04-29 | 2017-05-03 | Atyr 医药公司 | 与缬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
US9089588B2 (en) | 2010-05-03 | 2015-07-28 | Curna, Inc. | Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) |
AU2011248227B2 (en) | 2010-05-03 | 2016-12-01 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
EP2566515B1 (en) | 2010-05-03 | 2017-08-02 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
WO2011140135A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
KR20130079384A (ko) | 2010-05-03 | 2013-07-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
CN102971428A (zh) | 2010-05-04 | 2013-03-13 | 巴斯夫欧洲公司 | 对除草剂具有增加的耐受性的植物 |
JP6008844B2 (ja) | 2010-05-04 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | p38MULTI−tRNA合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
CA2797910A1 (en) | 2010-05-06 | 2011-11-10 | Pioneer Hi-Bred International, Inc. | Maize acc synthase 3 gene and protein and uses thereof |
GB201007834D0 (en) | 2010-05-11 | 2010-06-23 | Vib Vzw | Growth promoting fusion proteins |
CN103429739B (zh) | 2010-05-12 | 2018-11-13 | 哥伦比亚大学纽约管理委员会 | 制备产生和分泌胰岛素的肠内分泌细胞的方法 |
EP2569431B1 (en) | 2010-05-13 | 2015-09-23 | Sarepta Therapeutics, Inc. | Methods for identifying compounds which modulate interleukins 17 and 23 signaling activity |
CA2799197C (en) | 2010-05-14 | 2019-10-29 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
TWI586356B (zh) | 2010-05-14 | 2017-06-11 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
CA2799480C (en) | 2010-05-17 | 2020-12-15 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases |
EP2576783B1 (en) | 2010-05-26 | 2017-11-29 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
WO2011156278A1 (en) | 2010-06-07 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
AU2011268458B2 (en) | 2010-06-15 | 2014-06-12 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
US20130160165A1 (en) | 2010-06-24 | 2013-06-20 | BASF Plant Science Company BmbH | Plants Having Enhanced Yield-Related Traits and Method for Making the Same |
AU2011268562A1 (en) | 2010-06-25 | 2013-01-10 | Basf Plant Science Company Gmbh | Plants with enhanced yield-related traits and producing method thereof |
WO2012003207A2 (en) | 2010-07-01 | 2012-01-05 | E. I. Du Pont De Nemours And Company | Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding pae and pae-like polypeptides |
EA201390077A1 (ru) | 2010-07-08 | 2013-06-28 | Байер Кропсайенс Нв | Белок-переносчик глюкозинолатов и его применения |
CA2804416C (en) | 2010-07-12 | 2020-04-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
NO2593547T3 (zh) | 2010-07-14 | 2018-04-14 | ||
EP2593555A4 (en) | 2010-07-16 | 2014-02-26 | Basf Plant Science Co Gmbh | PLANTS HAVING ENHANCED YIELD LINKS AND METHOD FOR OBTAINING SAME |
UA112969C2 (uk) | 2010-08-03 | 2016-11-25 | Сібас Юс Ллс | Рослина, стійка до одного або більше ррх-інгібуючих гербіцидів, яка містить мутантний ген протопорфіриноген ix оксидази (ррх) |
US20120122223A1 (en) | 2010-08-03 | 2012-05-17 | Cibus Us Llc | Mutated protoporphyrinogen ix oxidase (ppx) genes |
US9139842B2 (en) | 2010-08-13 | 2015-09-22 | Pioneer Hi-Bred International, Inc. | Methods and compositions for targeting sequences of interest to the chloroplast |
CA2809214A1 (en) | 2010-08-24 | 2012-03-01 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and method for making the same |
JP5964304B2 (ja) | 2010-08-25 | 2016-08-03 | エータイアー ファーマ, インコーポレイテッド | チロシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
EP2426204A1 (en) | 2010-09-02 | 2012-03-07 | Ludwig-Maximilians-Universität München | Spontaneous nodule organogenesis in plants |
WO2012028673A1 (en) | 2010-09-02 | 2012-03-08 | Ludwig-Maximilians-Universitaet Muenchen | Spontaneous organogenesis in plants |
AU2011312205B2 (en) | 2010-10-05 | 2015-08-13 | Curis, Inc. | Mutant smoothened and methods of using the same |
WO2012047956A2 (en) | 2010-10-06 | 2012-04-12 | Opko Curna Llc | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
CN103517990A (zh) | 2010-10-07 | 2014-01-15 | 通用医疗公司 | 癌症生物标志物 |
CN103180445B (zh) | 2010-10-22 | 2018-02-16 | 库尔纳公司 | 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病 |
CN103201387B (zh) | 2010-10-27 | 2018-02-02 | 库尔纳公司 | 通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病 |
WO2012063200A1 (en) | 2010-11-10 | 2012-05-18 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and method for making the same |
EP3260540A1 (en) | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
US8609621B2 (en) | 2010-11-15 | 2013-12-17 | E I Du Pont De Nemours And Company | Acid-cleavable linkers exhibiting altered rates of acid hydrolysis |
AU2011329777B2 (en) | 2010-11-17 | 2016-06-09 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
JP6071893B2 (ja) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療 |
US9834778B2 (en) | 2010-12-06 | 2017-12-05 | Basf Plant Science Company Gmbh | Synthetic arcelin-5 promoter and methods of use thereof |
BR112013014778A2 (pt) | 2010-12-16 | 2017-06-06 | Basf Se | método para controlar a vegetação indesejável em um sítio de cultivo de plantas, método para identificar uma herbicida derivado de benzoxazinona, método de identificação de uma sequência de nucleotídeos, ácido nucleico isolado, célula vegetal transgênica, planta transgênica e semente |
PL2655657T3 (pl) | 2010-12-22 | 2019-06-28 | Pioneer Hi-Bred International, Inc. | Loci QTL związane z odpornością polową całej rośliny na Sclerotinię oraz sposoby jej identyfikacji |
WO2012097261A2 (en) | 2011-01-14 | 2012-07-19 | The General Hospital Corporation | Methods targeting mir-128 for regulating cholesterol/lipid metabolism |
WO2012098517A1 (en) | 2011-01-20 | 2012-07-26 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and method for making the same |
US9688719B2 (en) | 2011-01-27 | 2017-06-27 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
US9243034B2 (en) | 2011-01-27 | 2016-01-26 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
EA030578B1 (ru) | 2011-02-01 | 2018-08-31 | Колорадо Уит Рисерч Фаундейшн, Инк. | РАСТЕНИЯ, УСТОЙЧИВЫЕ К ГЕРБИЦИДАМ, ВОЗДЕЙСТВУЮЩИМ НА АЦЕТИЛ-КоА КАРБОКСИЛАЗУ |
DK2670404T3 (en) | 2011-02-02 | 2018-11-19 | Univ Princeton | CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS |
KR101697396B1 (ko) | 2011-02-02 | 2017-01-17 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자(ctgf)를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법 |
US9273336B2 (en) | 2011-02-21 | 2016-03-01 | E. I. Du Pont De Nemours And Company | Recombinant host cells having an increase in buoyant density |
AR085394A1 (es) | 2011-02-25 | 2013-09-25 | Univ Nac De La Plata Unlp | Proteasa de plantas |
US20130340120A1 (en) | 2011-02-28 | 2013-12-19 | Basf Plant Science Company Gmbh | Plants Having Enhanced Yield-Related Traits and Producing Methods Thereof |
US20140033368A1 (en) | 2011-02-28 | 2014-01-30 | Valerie Frankard | Plants Having Enhanced Yield-Related Traits and Producing Methods Thereof |
WO2012117368A1 (en) | 2011-03-01 | 2012-09-07 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and producing methods thereof |
US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
CA2832910C (en) | 2011-04-12 | 2019-07-02 | Cynthia Lander | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
CA2833876A1 (en) | 2011-04-29 | 2012-11-01 | Pioneer Hi-Bred International, Inc. | Down-regulation of a homeodomain-leucine zipper i-class homeobox gene for improved plant performance |
CA2834183A1 (en) | 2011-05-19 | 2012-11-22 | Enrique ROJO DE LA VIESCA | Process for modifying the architecture and improving the yield of crop plants |
CN103620036B (zh) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病 |
WO2012170347A1 (en) | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
EP2721160A2 (en) | 2011-06-14 | 2014-04-23 | Synthon Biopharmaceuticals B.V. | Compositions and methods for making and biocontaining auxotrophic transgenic plants |
WO2013009935A2 (en) | 2011-07-12 | 2013-01-17 | Two Blades Foundation | Late blight resistance genes |
WO2013012643A1 (en) | 2011-07-15 | 2013-01-24 | Syngenta Participations Ag | Polynucleotides encoding trehalose-6-phosphate phosphatase and methods of use thereof |
WO2013012788A2 (en) | 2011-07-15 | 2013-01-24 | Syngenta Participations Ag | Methods of increasing yield and stress tolerance in a plant |
EP3112465A3 (en) | 2011-08-01 | 2017-04-12 | BASF Plant Science Company GmbH | Method for identification and isolation of terminator sequences causing enhanced transcription |
ES2856091T3 (es) | 2011-09-14 | 2021-09-27 | Univ Northwestern | Nanoconjugados capaces de atravesar la barrera hematoencefálica |
WO2013040429A1 (en) | 2011-09-14 | 2013-03-21 | Rana Therapeutics Inc. | Multimeric oligonucleotide compounds |
US10184151B2 (en) | 2011-10-11 | 2019-01-22 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
AR088515A1 (es) | 2011-10-25 | 2014-06-18 | Pioneer Hi Bred Int | Metodos para alterar la composicion de la pared celular vegetal para obtener produccion de biocombustible y digestibilidad de silaje mejoradas |
BR112014010537A2 (pt) | 2011-10-31 | 2017-05-02 | Pioneer Hi Bred Int | método para modular a sensibilidade ao etileno, planta transgênica, proteína isolada, sequência de polinucleotídeos isolada, polipeptídeo com atividade regulatória de etileno, método para aumentar o rendimento em uma planta, método para melhorar um parâmetro agronômico de uma planta, método de seleção assistida por marcador de uma planta |
JP2015502365A (ja) | 2011-12-12 | 2015-01-22 | オンコイミューニン,インコーポレイティド | オリゴヌクレオチドのイン−ビボ送達 |
BR112014020119A2 (pt) | 2012-02-13 | 2020-10-27 | Gamida-Cell Ltd | cultura de células-tronco mesenquimais |
WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
WO2013138309A1 (en) | 2012-03-13 | 2013-09-19 | Pioneer Hi-Bred International, Inc. | Genetic reduction of male fertility in plants |
CN104703998B (zh) | 2012-03-13 | 2020-08-21 | 先锋国际良种公司 | 植物中雄性育性的遗传减少 |
ES2694592T3 (es) | 2012-03-15 | 2018-12-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF |
WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
WO2013154799A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
JP2015518485A (ja) | 2012-04-20 | 2015-07-02 | アプタミアール セラピューティクス インコーポレイテッド | 熱発生のmiRNA調節剤 |
WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
DK2850189T3 (en) | 2012-05-16 | 2019-02-25 | Translate Bio Ma Inc | COMPOSITIONS AND PROCEDURES FOR MODULATING GENEPRESSION |
SG11201407483YA (en) | 2012-05-16 | 2014-12-30 | Rana Therapeutics Inc | Compositions and methods for modulating smn gene family expression |
US10045499B2 (en) | 2012-05-24 | 2018-08-14 | Iowa State University Research Foundation, Inc. | Arabidopsis nonhost resistance gene(s) and use thereof to engineer disease resistant plants |
WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
AR091489A1 (es) | 2012-06-19 | 2015-02-11 | Basf Se | Plantas que tienen una mayor tolerancia a herbicidas inhibidores de la protoporfirinogeno oxidasa (ppo) |
EP2677035A1 (en) | 2012-06-22 | 2013-12-25 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US20150216892A1 (en) | 2012-08-03 | 2015-08-06 | Aptamir Therapeutics, Inc. | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders |
CN104736551B (zh) | 2012-08-15 | 2017-07-28 | Ionis制药公司 | 使用改进的封端方案制备寡聚化合物的方法 |
US10006041B2 (en) | 2012-08-16 | 2018-06-26 | Vib Vzw | Means and methods for altering the lignin pathway in plants |
WO2014037735A1 (en) | 2012-09-10 | 2014-03-13 | University Of Leicester | Atsp1, an e3 ubiquitin ligase, and its use |
US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
CN104918639B (zh) | 2012-10-22 | 2018-01-26 | 萨拜格Rfa公司 | 用于将治疗剂递送到活细胞和细胞核中的*** |
US20150299718A1 (en) | 2012-11-20 | 2015-10-22 | Rajeev Gupta | Engineering Plants for Efficient Uptake and Utilization of Urea to Improve |
AU2013361220A1 (en) | 2012-12-21 | 2015-04-02 | Pioneer Hi-Bred International, Inc. | Compositions and methods for auxin-analog conjugation |
EP2754715A1 (en) | 2013-01-11 | 2014-07-16 | Consejo Superior De Investigaciones Científicas (CSIC) | Stress tolerant plants |
US10231397B2 (en) | 2013-01-29 | 2019-03-19 | Basf Plant Science Company Gmbh | Fungal resistant plants expressing EIN2 |
CA2897485A1 (en) | 2013-01-29 | 2014-08-07 | Basf Plant Science Company Gmbh | Fungal resistant plants expressing hcp6 |
US10462994B2 (en) | 2013-01-29 | 2019-11-05 | Basf Plant Science Company Gmbh | Fungal resistant plants expressing HCP7 |
WO2014121436A1 (en) | 2013-02-05 | 2014-08-14 | Plant Bioscience Limited | Transgenic plants |
US10465204B2 (en) | 2013-03-08 | 2019-11-05 | Basf Plant Science Company Gmbh | Fungal resistant plants expressing MybTF |
US20160002648A1 (en) | 2013-03-11 | 2016-01-07 | Mei Guo | Genes for improving nutrient uptake and abiotic stress tolerance in plants |
US10329574B2 (en) | 2013-03-12 | 2019-06-25 | E I Du Pont De Nemours And Company | Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof |
US9803214B2 (en) | 2013-03-12 | 2017-10-31 | Pioneer Hi-Bred International, Inc. | Breeding pair of wheat plants comprising an MS45 promoter inverted repeat that confers male sterility and a construct that restores fertility |
WO2014164074A1 (en) | 2013-03-13 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Enhanced nitrate uptake and nitrate translocation by over-expressing maize functional low-affinity nitrate transporters in transgenic maize |
WO2014164116A1 (en) | 2013-03-13 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Functional expression of bacterial major facilitator superfamily (sfm) gene in maize to improve agronomic traits and grain yield |
US20160024513A1 (en) | 2013-03-14 | 2016-01-28 | Pioneer Hi-Bred International Inc. | Maize stress related transcription factor 18 and uses thereof |
AU2014236181B2 (en) | 2013-03-14 | 2020-03-19 | Cibus Europe B.V. | Mutated allene oxide synthase 2 (AOS2) genes |
IL290273B2 (en) | 2013-03-15 | 2024-03-01 | Cibus Us Llc | Methods and compositions for increasing the efficiency of targeted gene modification through the use of gene repair with oligonucleotides - mediators |
IL241145B (en) | 2013-03-15 | 2022-07-01 | Cibus Us Llc | Methods and compositions for increasing the efficiency of targeted gene modification using oligonucleotide-mediated gene repair |
CN105247056A (zh) | 2013-03-15 | 2016-01-13 | 先锋国际良种公司 | Acc脱氨酶表达的调节 |
US9957515B2 (en) | 2013-03-15 | 2018-05-01 | Cibus Us Llc | Methods and compositions for targeted gene modification |
CN105143454A (zh) | 2013-03-15 | 2015-12-09 | 先锋国际良种公司 | Acc氧化酶多核苷酸和多肽的组合物和使用方法 |
US10017778B2 (en) | 2013-03-21 | 2018-07-10 | Vib Vzw | Means and methods for the reduction of photorespiration in crops |
AU2014259755B2 (en) | 2013-05-01 | 2018-08-30 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein (a) expression |
JP6869720B2 (ja) | 2013-06-13 | 2021-05-12 | アンチセンス セラピューティクス リミテッド | 併用療法 |
EP2816115A1 (en) | 2013-06-17 | 2014-12-24 | BASF Plant Science Company GmbH | Plants having one or more enhanced yield-related traits and a method for making the same |
EP3013850B1 (en) | 2013-06-24 | 2018-07-25 | Ramot at Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
US11459579B2 (en) | 2013-07-09 | 2022-10-04 | Board Of Trustees Of Michigan State University | Transgenic plants produced with a K-domain, and methods and expression cassettes related thereto |
BR112015032956B1 (pt) | 2013-07-09 | 2022-09-13 | Board Of Trustees Of Michigan State University | Método para produzir uma planta transgênica e cassete de expressão |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
EP2896698A1 (en) | 2014-01-17 | 2015-07-22 | BASF Plant Science Company GmbH | Plants having one or more enhanced yield-related traits and a method for making the same |
WO2015116680A1 (en) | 2014-01-30 | 2015-08-06 | Two Blades Foundation | Plants with enhanced resistance to phytophthora |
SI3099333T1 (sl) | 2014-01-31 | 2021-04-30 | Temple University of the Commonwealth System of Higher Education 1938 Liacouras Walk | BAG3 kot tarča za terapijo srčne odpovedi |
ES2694857T3 (es) | 2014-02-04 | 2018-12-27 | Genentech, Inc. | Smoothened mutante y métodos de uso de la misma |
AU2015229095B2 (en) | 2014-03-14 | 2022-01-27 | Cibus Europe B.V. | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair |
WO2015142910A1 (en) | 2014-03-17 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
WO2015143246A1 (en) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
AU2015240761B2 (en) | 2014-04-01 | 2019-09-12 | Biogen Ma Inc. | Compositions for modulating SOD-1 expression |
WO2015150465A2 (en) | 2014-04-03 | 2015-10-08 | Basf Se | Plants having increased tolerance to herbicides |
WO2015164693A1 (en) | 2014-04-24 | 2015-10-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
SG10201809953QA (en) | 2014-05-01 | 2018-12-28 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating complement factor b expression |
WO2015171603A1 (en) | 2014-05-06 | 2015-11-12 | Two Blades Foundation | Methods for producing plants with enhanced resistance to oomycete pathogens |
CA2953216C (en) | 2014-06-04 | 2020-12-22 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
KR102524543B1 (ko) | 2014-06-10 | 2023-04-20 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드 |
US10301624B2 (en) | 2014-06-25 | 2019-05-28 | The General Hospital Corporation | Targeting human satellite II (HSATII) |
US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
CA2954201A1 (en) | 2014-07-08 | 2016-01-14 | Vib Vzw | Means and methods to increase plant yield |
EP3169778B1 (en) | 2014-07-14 | 2023-10-25 | Washington State University | Nanos knock-out that ablates germline cells |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
EP3663403A1 (en) | 2014-09-26 | 2020-06-10 | University of Massachusetts | Rna-modulating agents |
WO2016057515A2 (en) | 2014-10-06 | 2016-04-14 | Altria Client Services Llc | Genetic control of axillary bud growth in tobacco plants |
AU2015350151A1 (en) | 2014-11-17 | 2017-06-01 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US20170369902A1 (en) | 2014-12-16 | 2017-12-28 | Pioneer Hi-Bred International, Inc. | Restoration of male fertility in wheat |
US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
WO2016115490A1 (en) | 2015-01-16 | 2016-07-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of dux4 |
CR20170382A (es) | 2015-01-21 | 2018-02-16 | Basf Se | Plantas que tienen una mayor tolerancia a herbicidas |
US10793868B2 (en) | 2015-02-03 | 2020-10-06 | Institute Of Genetics And Developmental Biology Chinese Academy Of Sciences | Plants with increased seed size |
US10485196B2 (en) | 2015-02-03 | 2019-11-26 | The Institute Of Genetics And Developmental Biology Chinese Academy Of Scinces | Rice plants with altered seed phenotype and quality |
WO2016124515A1 (en) | 2015-02-04 | 2016-08-11 | Basf Plant Science Company Gmbh | Method of increasing resistance against soybean rust in transgenic plants by increasing the scopoletin content |
GB201501941D0 (en) | 2015-02-05 | 2015-03-25 | British American Tobacco Co | Method |
WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
AR103649A1 (es) | 2015-02-11 | 2017-05-24 | Basf Se | Hidroxifenilpiruvato dioxigenasas resistentes a herbicidas |
GB201502409D0 (en) | 2015-02-13 | 2015-04-01 | British American Tobacco Co | Method |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
WO2016145234A2 (en) | 2015-03-12 | 2016-09-15 | Moerae Matrix, Inc. | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same |
US10717998B2 (en) | 2015-03-18 | 2020-07-21 | Basf Se | Recombinant microorganism for improved production of fine chemicals |
US10961532B2 (en) | 2015-04-07 | 2021-03-30 | The General Hospital Corporation | Methods for reactivating genes on the inactive X chromosome |
WO2016167780A1 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
WO2016182881A1 (en) | 2015-05-09 | 2016-11-17 | Two Blades Foundation | Late blight resistance gene from solanum americanum and methods of use |
RU2017146342A (ru) | 2015-06-04 | 2019-07-10 | Басф Се | Рекомбинантный микроорганизм для улучшенного получения химических продуктов тонкого органического синтеза |
KR20180011324A (ko) | 2015-06-12 | 2018-01-31 | 바스프 에스이 | 알라닌의 개선된 제조를 위한 재조합 미생물 |
US20180161429A1 (en) | 2015-06-26 | 2018-06-14 | Beth Israel Deaconess Medical Center Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
AU2016287499B2 (en) | 2015-06-29 | 2022-08-04 | Caris Science, Inc. | Therapeutic oligonucleotides |
CA2993652A1 (en) | 2015-07-28 | 2017-02-02 | Caris Science, Inc. | Targeted oligonucleotides |
EP4285912A2 (en) | 2015-09-25 | 2023-12-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
WO2017062790A1 (en) | 2015-10-09 | 2017-04-13 | Two Blades Foundation | Cold shock protein receptors and methods of use |
EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
EP3370734B1 (en) | 2015-11-05 | 2023-01-04 | Children's Hospital Los Angeles | Antisense oligo for use in treating acute myeloid leukemia |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
EP3389670A4 (en) | 2015-12-04 | 2020-01-08 | Ionis Pharmaceuticals, Inc. | METHODS OF TREATING BREAST CANCER |
WO2017099579A1 (en) | 2015-12-07 | 2017-06-15 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
WO2017120365A1 (en) | 2016-01-05 | 2017-07-13 | Ionis Pharmaceuticals, Inc. | Methods for reducing lrrk2 expression |
CN109071625A (zh) | 2016-02-04 | 2018-12-21 | 柯瑞斯公司 | 平滑化突变体和其使用方法 |
US11542515B2 (en) | 2016-02-09 | 2023-01-03 | Cibus Us Llc | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair |
WO2017147087A1 (en) | 2016-02-25 | 2017-08-31 | The Brigham And Women's Hospital, Inc. | Treatment methods for fibrosis targeting smoc2 |
JP7015243B2 (ja) | 2016-03-11 | 2022-02-02 | アルトリア クライアント サーヴィシーズ リミテッド ライアビリティ カンパニー | 吸枝が減少又は消失したタバコ植物及びタバコ製品を生産する組成物及び方法 |
EP3429690A4 (en) | 2016-03-16 | 2019-10-23 | Ionis Pharmaceuticals, Inc. | METHOD FOR MODULATING KEAP1 |
WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
EP3430137A4 (en) | 2016-03-18 | 2019-11-06 | Caris Science, Inc. | OLIGONUCLEOTIDE THONES AND USES THEREOF |
HUE056865T2 (hu) | 2016-03-30 | 2022-03-28 | Basf Se | N-Butil-akrilát fermentatív elõállítása alkohol-acil-transzferáz enzim segítségével |
US10563216B2 (en) | 2016-04-18 | 2020-02-18 | Bloomsburg University of Pennsylvania | Compositions and methods of delivering molecules to plants |
KR20230038804A (ko) | 2016-04-29 | 2023-03-21 | 바스프 플랜트 사이언스 컴퍼니 게엠베하 | 표적 핵산의 변형을 위한 개선된 방법 |
EP3054014A3 (en) | 2016-05-10 | 2016-11-23 | BASF Plant Science Company GmbH | Use of a fungicide on transgenic plants |
EA201892517A1 (ru) | 2016-05-20 | 2019-05-31 | Басф Агро Б.В. | Двойные транзитные пептиды для нацеливания полипептидов |
BR112018072479B1 (pt) | 2016-05-24 | 2023-01-31 | Basf Se | Método para controlar o crescimento de ervas daninhas, uso do composto de fórmula (i) e uso da composição |
IL306052A (en) | 2016-05-25 | 2023-11-01 | Caris Science Inc | Oligonucleotide probes and their uses |
JP6995783B2 (ja) | 2016-05-26 | 2022-02-04 | ヌンヘムス、ベスローテン、フェンノートシャップ | 種なし果実を実らせる植物 |
CA3023514A1 (en) | 2016-06-17 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
MX2018015798A (es) | 2016-06-22 | 2019-07-12 | Univ North Carolina State | Método para incrementar la eficiencia de uso de nitrógeno y/o la eficiencia de utilización de nitrógeno en plantas. |
EP3481430A4 (en) | 2016-07-11 | 2020-04-01 | Translate Bio Ma, Inc. | NUCLEIC ACID CONJUGATES AND USES THEREOF |
EA201990308A1 (ru) | 2016-07-15 | 2019-07-31 | Басф Се | Растения с повышенной устойчивостью к гербицидам |
CN109790153A (zh) | 2016-07-27 | 2019-05-21 | 巴斯夫农业公司 | 具有增加的除草剂耐受性的植物 |
WO2018019845A1 (en) | 2016-07-29 | 2018-02-01 | Basf Se | Method for controlling ppo resistant weeds |
CA3030354A1 (en) | 2016-07-29 | 2018-02-01 | Basf Se | Method for controlling ppo resistant weeds |
NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
WO2018024696A1 (en) | 2016-08-05 | 2018-02-08 | Basf Se | Method for controlling ppo resistant weeds |
EP3278667A1 (en) | 2016-08-05 | 2018-02-07 | Basf Se | Method for controlling ppo-inhibitor resistant weeds |
WO2018024695A1 (en) | 2016-08-05 | 2018-02-08 | Basf Se | Method for controlling ppo resistant weeds |
US11193136B2 (en) | 2016-08-09 | 2021-12-07 | Vib Vzw | Cellulose synthase inhibitors and mutant plants |
EP3281523A1 (en) | 2016-08-09 | 2018-02-14 | Basf Se | Method for controlling ppo resistant weeds |
US20190166841A1 (en) | 2016-08-09 | 2019-06-06 | Basf Se | Method for Controlling PPO Resistant Weeds |
EP3281525A1 (en) | 2016-08-09 | 2018-02-14 | Basf Se | Method for controlling ppo resistant weeds |
AU2017311447B2 (en) | 2016-08-09 | 2022-03-31 | Basf Se | Method for controlling PPO resistant weeds |
US11723365B2 (en) | 2016-08-09 | 2023-08-15 | Basf Se | Method for controlling PPO resistant weeds |
EP3281524A1 (en) | 2016-08-09 | 2018-02-14 | Basf Se | Method for controlling ppo resistant weeds |
WO2018067900A1 (en) | 2016-10-06 | 2018-04-12 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
US10647989B2 (en) | 2016-10-07 | 2020-05-12 | Altria Client Services Llc | Composition and methods for producing tobacco plants and products having reduced tobacco-specific nitrosamines (TSNAs) |
US11459568B2 (en) | 2016-10-31 | 2022-10-04 | University Of Massachusetts | Targeting microRNA-101-3p in cancer therapy |
JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
US11033570B2 (en) | 2016-12-02 | 2021-06-15 | Cold Spring Harbor Laboratory | Modulation of Lnc05 expression |
WO2018112356A1 (en) | 2016-12-16 | 2018-06-21 | Two Blades Foundation | Late blight resistance genes and methods of use |
CN110382702A (zh) | 2016-12-20 | 2019-10-25 | 巴斯夫农业公司 | 具有增加的除草剂耐性的植物 |
RU2019117393A (ru) | 2016-12-27 | 2020-12-07 | Инбиоз Н.В. | Синтез сиалированных соединений in vivo |
WO2018140214A1 (en) | 2017-01-24 | 2018-08-02 | Pioneer Hi-Bred International, Inc. | Nematicidal protein from pseudomonas |
US20190367937A1 (en) | 2017-02-09 | 2019-12-05 | Fujian Agriculture And Forestry University | Expression of a phosphate transporter for improving plant yield |
US11180756B2 (en) | 2017-03-09 | 2021-11-23 | Ionis Pharmaceuticals | Morpholino modified oligomeric compounds |
CA3060514A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
US11445692B2 (en) | 2017-05-15 | 2022-09-20 | Equi-Nom Ltd. | Quantitative trait loci (QTL) associated with shatter resistant capsules in sesame and uses thereof |
CN111542608A (zh) | 2017-07-28 | 2020-08-14 | 双刃基金会 | 马铃薯y病毒抗性基因及使用方法 |
US11197884B2 (en) | 2017-08-18 | 2021-12-14 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | MODULATORS OF SMAD7 EXPRESSION |
US11104912B2 (en) | 2017-09-11 | 2021-08-31 | Altria Client Services Llc | Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers |
TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
WO2019108619A1 (en) | 2017-11-28 | 2019-06-06 | Two Blades Foundation | Methods and compositions for enhancing the disease resistance of plants |
UA127971C2 (uk) | 2017-11-29 | 2024-02-28 | Басф Се | Спосіб контролю за небажаною рослинністю на ділянці вирощуванння рослини |
WO2019125804A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Nucleases and methods for making and using them |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
US11034969B2 (en) | 2017-12-22 | 2021-06-15 | Altria Client Services Llc | Plant comprising recombinant polynucleotides encoding a pigment regulatory transcription factor with a tissue-preferred promoter |
CN107868123B (zh) | 2017-12-25 | 2020-05-12 | 中国农业科学院作物科学研究所 | 一种同时提高植物产量和抗性的基因及其应用 |
US11359208B2 (en) | 2018-01-09 | 2022-06-14 | Cibus Us Llc | Shatterproof genes and mutations |
US11732271B2 (en) | 2018-01-12 | 2023-08-22 | The Sainsbury Laboratory | Stem rust resistance genes and methods of use |
MX2020007369A (es) | 2018-01-15 | 2020-10-28 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de dnm2. |
AU2019210093A1 (en) | 2018-01-17 | 2020-07-09 | Basf Se | Plants having increased tolerance to herbicides |
BR112020014242A2 (pt) | 2018-02-14 | 2020-12-15 | Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences | Métodos de aumento da eficiência de uso de nutriente |
WO2019169243A1 (en) | 2018-03-02 | 2019-09-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-beta precursor protein |
MX2020009147A (es) | 2018-03-02 | 2020-09-28 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de irf4. |
EP3768694A4 (en) | 2018-03-22 | 2021-12-29 | Ionis Pharmaceuticals, Inc. | Methods for modulating fmr1 expression |
WO2019186514A2 (en) | 2018-03-30 | 2019-10-03 | Rheinische Friedrich-Wilhelms-Universitat Bonn | Aptamers for targeted activaton of t cell-mediated immunity |
EP4062774B1 (en) | 2018-04-03 | 2024-03-20 | Altria Client Services LLC | Composition and methods for producing tobacco plants and products having increased phenylalanine and reduced tobacco-specific nitrosamines (tsnas) |
CN112272516B (zh) | 2018-04-06 | 2023-05-30 | 儿童医疗中心有限公司 | 用于体细胞重新编程和调整印记的组合物和方法 |
MX2020010721A (es) | 2018-04-11 | 2020-11-06 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de ezh2. |
US11732250B2 (en) | 2018-04-26 | 2023-08-22 | Basf Se | Lipase enzymes |
US20210115422A1 (en) | 2018-05-03 | 2021-04-22 | Basf Se | Amylase enzymes |
US20210355497A1 (en) | 2018-05-09 | 2021-11-18 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing fxi expression |
JP2021522800A (ja) | 2018-05-09 | 2021-09-02 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Atxn3発現を低減するための化合物及び方法 |
WO2019219933A1 (en) | 2018-05-17 | 2019-11-21 | Vib Vzw | An engineered combinatorial module of transcription factors to boost production of monoterpenoid indole alkaloids |
US11833168B2 (en) | 2018-06-14 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing STMN2 expression |
US11291176B2 (en) | 2018-06-15 | 2022-04-05 | Nunhems B.V. | Seedless watermelon plants comprising modifications in an ABC transporter gene |
MX2020013653A (es) | 2018-06-27 | 2021-03-02 | Ionis Pharmaceuticals Inc | Compuestos y metodos para la reduccion de la expresion de lrrk2. |
WO2020010059A1 (en) | 2018-07-02 | 2020-01-09 | Aptamir Therapeutics, Inc. | Targeted delivery of therapeutic agents to human adipocytes |
EP3826645A4 (en) | 2018-07-25 | 2023-05-17 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR REDUCING ATXN2 EXPRESSION |
EP3843845A4 (en) | 2018-08-29 | 2022-05-11 | University Of Massachusetts | INHIBITION OF PROTEIN KINASE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA |
US20230183728A1 (en) | 2018-09-07 | 2023-06-15 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of pufa in plants |
CN113412332A (zh) | 2018-09-07 | 2021-09-17 | 巴斯夫植物科学有限公司 | 用于在植物中产生高水平pufa的改进方法 |
CA3110656A1 (en) | 2018-09-07 | 2020-03-12 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of pufa in plants |
MX2021004433A (es) | 2018-10-18 | 2021-07-06 | Basf Se | Metodo para la produccion de acido acrilico o sus sales. |
TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
JP2022509059A (ja) | 2018-11-15 | 2022-01-20 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Irf5発現の調節因子 |
CA3124395A1 (en) | 2018-12-20 | 2020-06-25 | Basf Plant Science Company Gmbh | Native delivery of biomolecules into plant cells using ionic complexes with cell-penetrating peptides |
MX2021008768A (es) | 2019-01-22 | 2022-01-06 | Basf Se | Metodo para la produccion de acido 4-ciano benzoico o sus sales. |
US20200239899A1 (en) | 2019-01-24 | 2020-07-30 | Altria Client Services Llc | Tobacco Plants Comprising Reduced Nicotine and Reduced Tobacco Specific Nitrosamines |
US11214803B2 (en) | 2019-01-31 | 2022-01-04 | Ionis Pharmaceuticals, Inc. | Modulators of YAP1 expression |
GB201902253D0 (en) | 2019-02-19 | 2019-04-03 | Univ Court Univ Of Glasgow | Methods for optogenetic manipulation of stomatal function |
WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
MX2021010152A (es) | 2019-02-27 | 2021-09-14 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de malat1. |
US20220186200A1 (en) | 2019-03-11 | 2022-06-16 | Basf Se | Amylases and methods for making and using them |
US20220145320A1 (en) | 2019-03-14 | 2022-05-12 | Rothamsted Research Limited | Genetically modified plants with enhanced drought tolerance |
EP3947665A2 (en) | 2019-03-25 | 2022-02-09 | Basf Se | Amylase enzymes |
EP3947664A2 (en) | 2019-03-25 | 2022-02-09 | Basf Se | Amylase enzymes |
WO2020193532A1 (en) | 2019-03-25 | 2020-10-01 | Basf Se | Cleaning composition having amylase enzymes |
CN117431244A (zh) | 2019-03-29 | 2024-01-23 | Ionis制药公司 | 用于调节ube3a-ats的化合物和方法 |
EP3966334A1 (en) | 2019-05-10 | 2022-03-16 | Basf Se | Regulatory nucleic acid molecules for enhancing gene expression in plants |
AU2020305509A1 (en) | 2019-06-27 | 2022-01-20 | Basf Plant Science Company Gmbh | Methods for transformation of fungal spores |
CN114450405A (zh) | 2019-06-27 | 2022-05-06 | 双刃基金会 | 工程化atrlp23模式识别受体及使用方法 |
WO2021011348A1 (en) | 2019-07-12 | 2021-01-21 | The Regents Of The University Of California | Plants with enhanced resistance to bacterial pathogens |
EP3956450A4 (en) | 2019-07-26 | 2022-11-16 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATION OF GFAP |
KR20220062517A (ko) | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
JP2022545465A (ja) | 2019-08-22 | 2022-10-27 | ビーエーエスエフ ソシエタス・ヨーロピア | アミラーゼバリアント |
CA3150334A1 (en) | 2019-09-12 | 2021-03-18 | Frank Meulewaeter | REGULATORY NUCLEIC ACID MOLECULES TO ENHANCE GENE EXPRESSION IN PLANTS |
WO2021058691A1 (en) | 2019-09-26 | 2021-04-01 | Basf Se | Method for the production of beta-alanine or salts thereof |
WO2021069387A1 (en) | 2019-10-07 | 2021-04-15 | Basf Se | Regulatory nucleic acid molecules for enhancing gene expression in plants |
AU2020396138A1 (en) | 2019-12-03 | 2022-06-16 | Basf Se | Regulatory nucleic acid molecules for enhancing gene expression in plants |
EP4077651A1 (en) | 2019-12-16 | 2022-10-26 | BASF Agricultural Solutions Seed US LLC | Codon-optimized cas9 endonuclease encoding polynucleotide |
AU2020410138A1 (en) | 2019-12-16 | 2022-06-23 | BASF Agricultural Solutions Seed US LLC | Precise introduction of DNA or mutations into the genome of wheat |
WO2021122080A1 (en) | 2019-12-16 | 2021-06-24 | BASF Agricultural Solutions Seed US LLC | Improved genome editing using paired nickases |
WO2021174019A1 (en) | 2020-02-28 | 2021-09-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating smn2 |
EP4114954A1 (en) | 2020-03-04 | 2023-01-11 | Basf Se | Method for the production of constitutive bacterial promoters conferring low to medium expression |
KR20220149567A (ko) | 2020-03-04 | 2022-11-08 | 바스프 에스이 | 이. 콜라이 및 바실루스에서의 발현을 위한 셔틀 벡터 |
EP4143321A2 (en) | 2020-05-01 | 2023-03-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating atxn1 |
BR112022022933A2 (pt) | 2020-05-15 | 2022-12-20 | Basf Se | Quinase 1 isolada, processos de produção de fosfato de isopentenila, construções recombinantes, vetores recombinantes, microrganismos recombinantes, composições, processos de produção de pirofosfato de isopentenila, métodos para a produção fermentativa de um ou mais isoprenoides e para produzir um microrganismo recombinante, método de cultura ou crescimento, construção de expressão e processo para bioconversão |
WO2022006134A2 (en) | 2020-06-29 | 2022-01-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating plp1 |
US11730133B2 (en) | 2020-10-21 | 2023-08-22 | Equi-Nom Ltd | High yield sesame |
MX2023005736A (es) | 2020-11-18 | 2023-05-25 | Ionis Pharmaceuticals Inc | Compuestos y metodos para modular la expresion de angiotensinogeno. |
CA3219611A1 (en) | 2021-05-11 | 2022-11-17 | Two Blades Foundation | Methods for preparing a library of plant disease resistance genes for functional testing for disease resistance |
CA3223192A1 (en) | 2021-06-18 | 2022-12-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ifnar1 expression |
WO2023012342A1 (en) | 2021-08-06 | 2023-02-09 | Kws Vegetables B.V. | Durable downy mildew resistance in spinach |
WO2023031161A1 (en) | 2021-09-03 | 2023-03-09 | BASF Agricultural Solutions Seed US LLC | Plants having increased tolerance to herbicides |
US11395470B1 (en) | 2021-09-14 | 2022-07-26 | Equi-Nom Ltd. | Sesame with high oil content and/or high yield |
WO2023043220A1 (ko) | 2021-09-16 | 2023-03-23 | 주식회사 큐마인 | Wfdc2의 발현을 조절하는 안티센스 화합물 |
AU2022356378A1 (en) | 2021-09-30 | 2024-05-02 | Two Blades Foundation | Plant disease resistance genes against stem rust and methods of use |
WO2023067192A1 (en) | 2021-10-21 | 2023-04-27 | Consejo Superior De Investigaciones Cientificas (Csic) | Methods for improving abiotic stress resistance |
WO2023105244A1 (en) | 2021-12-10 | 2023-06-15 | Pig Improvement Company Uk Limited | Editing tmprss2/4 for disease resistance in livestock |
WO2023118136A1 (en) | 2021-12-22 | 2023-06-29 | BASF Agricultural Solutions Seed US LLC | Improved screening method for genome edited events |
WO2023131616A1 (en) | 2022-01-05 | 2023-07-13 | Vib Vzw | Means and methods to increase abiotic stress tolerance in plants |
WO2023131637A1 (en) | 2022-01-06 | 2023-07-13 | Vib Vzw | Improved silage grasses |
WO2023144199A1 (en) | 2022-01-26 | 2023-08-03 | Vib Vzw | Plants having reduced levels of bitter taste metabolites |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024044352A1 (en) | 2022-08-26 | 2024-02-29 | The General Hospital Corporation | Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure |
WO2024083579A1 (en) | 2022-10-20 | 2024-04-25 | Basf Se | Regulatory nucleic acid molecules for enhancing gene expression in plants |
WO2024089011A1 (en) | 2022-10-26 | 2024-05-02 | BASF Agricultural Solutions Seed US LLC | Excision of recombinant dna from the genome of plant cells |
WO2024094678A2 (en) | 2022-11-02 | 2024-05-10 | Basf Se | Improved method for the production of natural vanillin |
WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4503151A (en) * | 1980-12-10 | 1985-03-05 | Research Corporation | Recombinant cDNA construction method and hybrid nucleotides useful in cloning |
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4882279A (en) * | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
EP0260032B1 (en) * | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
US4950599A (en) * | 1987-01-29 | 1990-08-21 | Wolf Bertling | Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments |
WO1990014092A1 (en) * | 1989-05-18 | 1990-11-29 | Cell Genesys, Inc. | Single-strand site-directed modification of mammalian genes in vivo |
JP3571337B2 (ja) * | 1992-02-11 | 2004-09-29 | セル ジェネシス,インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
JPH07506252A (ja) * | 1992-04-24 | 1995-07-13 | エス・アール・アイ・インターナシヨナル | 真核細胞内でのイン・ビボ相同配列ターゲッティング |
EP0656747A4 (en) * | 1992-08-21 | 1997-05-07 | Univ California | COMPOSITION AND METHOD FOR CHANGING DNA SEQUENCES BY HOMOLOGOUS RECOMBINATION. |
AU6527094A (en) * | 1993-03-31 | 1994-10-24 | Hybridon, Inc. | Modified oligonucleotides having improved anti-influenza activity |
-
1994
- 1994-12-09 EP EP95905337A patent/EP0733059B1/en not_active Expired - Lifetime
- 1994-12-09 PT PT95905337T patent/PT733059E/pt unknown
- 1994-12-09 CA CA002178729A patent/CA2178729A1/en not_active Abandoned
- 1994-12-09 DK DK95905337T patent/DK0733059T3/da active
- 1994-12-09 WO PCT/US1994/014181 patent/WO1995015972A1/en active IP Right Grant
- 1994-12-09 DE DE69425903T patent/DE69425903T2/de not_active Expired - Fee Related
- 1994-12-09 NZ NZ278490A patent/NZ278490A/en unknown
- 1994-12-09 US US08/353,657 patent/US5565350A/en not_active Expired - Lifetime
- 1994-12-09 AT AT95905337T patent/ATE196311T1/de not_active IP Right Cessation
- 1994-12-09 AU AU13995/95A patent/AU691550B2/en not_active Ceased
- 1994-12-09 JP JP51636795A patent/JP3585238B2/ja not_active Expired - Fee Related
- 1994-12-09 KR KR1019960703040A patent/KR100386337B1/ko not_active IP Right Cessation
- 1994-12-09 ES ES95905337T patent/ES2149962T3/es not_active Expired - Lifetime
- 1994-12-09 DE DE0733059T patent/DE733059T1/de active Pending
- 1994-12-09 CN CN94194935A patent/CN1048254C/zh not_active Expired - Fee Related
-
1996
- 1996-09-09 US US08/709,982 patent/US5756325A/en not_active Expired - Fee Related
-
1997
- 1997-12-02 US US08/982,866 patent/US5871984A/en not_active Expired - Fee Related
-
1998
- 1998-08-22 CN CN98118786A patent/CN1117866C/zh not_active Expired - Fee Related
-
2000
- 2000-12-04 GR GR20000402677T patent/GR3034988T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE196311T1 (de) | 2000-09-15 |
EP0733059A1 (en) | 1996-09-25 |
US5565350A (en) | 1996-10-15 |
US5756325A (en) | 1998-05-26 |
US5871984A (en) | 1999-02-16 |
DE733059T1 (de) | 1997-08-28 |
DK0733059T3 (da) | 2000-10-16 |
EP0733059B1 (en) | 2000-09-13 |
KR100386337B1 (ko) | 2004-03-24 |
CN1117866C (zh) | 2003-08-13 |
DE69425903T2 (de) | 2001-02-15 |
EP0733059A4 (en) | 1997-05-21 |
JPH09506511A (ja) | 1997-06-30 |
GR3034988T3 (en) | 2001-03-30 |
KR960706500A (ko) | 1996-12-09 |
DE69425903D1 (de) | 2000-10-19 |
CN1048254C (zh) | 2000-01-12 |
ES2149962T3 (es) | 2000-11-16 |
AU691550B2 (en) | 1998-05-21 |
CA2178729A1 (en) | 1995-06-15 |
CN1215755A (zh) | 1999-05-05 |
PT733059E (pt) | 2001-03-30 |
JP3585238B2 (ja) | 2004-11-04 |
NZ278490A (en) | 1998-03-25 |
AU1399595A (en) | 1995-06-27 |
WO1995015972A1 (en) | 1995-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1048254C (zh) | 用于将预定的改变引入靶基因中的化合物 | |
JP6888213B2 (ja) | 簡便で高効率の遺伝子改変非ヒト哺乳動物の作製方法 | |
US6573046B1 (en) | Eukaryotic use of improved chimeric mutational vectors | |
AU2020223370B2 (en) | Enzymes with RuvC domains | |
CN103388006B (zh) | 一种基因定点突变的构建方法 | |
KR20200103769A (ko) | 연장된 단일 가이드 rna 및 그 용도 | |
CN108463211A (zh) | 用于治疗肌联蛋白类肌病和其它肌联蛋白病变的材料和方法 | |
CN109475109A (zh) | 用于使用多个引导rna来破坏免疫耐受性的方法 | |
WO2010085699A2 (en) | Mammalian piggybac transposon and methods of use | |
JP6958917B2 (ja) | 遺伝子ノックイン細胞の作製方法 | |
EP4146800A1 (en) | Enzymes with ruvc domains | |
CN115058424A (zh) | 一种irf2bpl基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
CN113817734A (zh) | 一种hectd4基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
JP2023542976A (ja) | カーゴヌクレオチド配列を転位させるための系および方法 | |
CN110938629B (zh) | 特异性识别猪Wip1基因的成套sgRNA及其应用和产品 | |
CN113957070A (zh) | 一种chd2基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
KR20220039564A (ko) | 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도 | |
CN113897361A (zh) | 一种eef1b2基因敲除斑马鱼癫痫模型及其构建方法和应用 | |
US20240110167A1 (en) | Enzymes with ruvc domains | |
Gazaryan et al. | Microinjection of simian adenovirus SA7 (C-8) DNA into the mouse zygotes: differential distribution of viral DNA in organs | |
CN117965621A (zh) | 一种制备亮斑扁角水虻增重品系的方法及其核酸构建物 | |
CN117286169A (zh) | 一种由Tn7-CRISPR-Cas介导的需钠弧菌基因整合*** | |
CN113897360A (zh) | 一种eef1b2基因敲除斑马鱼癫痫模型及其应用 | |
Hamer | Recombinant DNA—an introduction | |
FKKT et al. | One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering (2013) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |